- 阻害剤
- 研究分野別
- PI3K/Akt/mTOR
- Epigenetics
- Methylation
- Immunology & Inflammation
- Protein Tyrosine Kinase
- Angiogenesis
- Apoptosis
- Autophagy
- ER stress & UPR
- JAK/STAT
- MAPK
- Cytoskeletal Signaling
- Cell Cycle
- TGF-beta/Smad
- 化合物ライブラリー
- 抗体
- 新製品
- お問い合わせ
Midostaurin
別名：PKC412, CGP 41251
Midostaurin is a multi-targeted kinase inhibitor, including PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC50 ranging from 80-500 nM.
-chemical-structure-s8064.gif)
CAS No. 120685-11-2
文献中Selleckの製品使用例（45）
製品安全説明書
現在のバッチを見る：
純度：
99.98%
99.98
Midostaurin関連製品
シグナル伝達経路
PKC阻害剤の選択性比較
Cell Data
| Cell Lines | Assay Type | Concentration | Incubation Time | 活性情報 | PMID |
|---|---|---|---|---|---|
| EOL-1 | Apoptosis assay | 10 nM | 72 hrs | Induction of apoptosis in human EOL-1 cells assessed as caspase-3 activation at 10 nM after 72 hrs by immunoblotting analysis | 29350920 |
| MOLM13 | Apoptosis assay | 10 nM | 72 hrs | Induction of apoptosis in human MOLM13 cells assessed as caspase-3 activation at 10 nM after 72 hrs by immunoblotting analysis | 29350920 |
| U937 | Cytotoxicity assay | 72 hrs | Cytotoxicity against FLT3-deficient human U937 cells assessed as cell growth inhibition after 72 hrs by MTS assay, GI50 = 1.4 μM. | 26081023 | |
| RS4:11 | Function assay | 72 hrs | Inhibition of wild type homozygous FLT3 in human RS4:11 cells assessed as cell growth inhibition after 72 hrs by MTS assay, GI50 = 0.4 μM. | 26081023 | |
| Sf9 | Function assay | 120 mins | Inhibition of recombinant GST-tagged VEGFR2 kinase domain (V789 to V1356) (unknown origin) expressed in insect Sf9 cells using polyGlu4:Tyr peptide as substrate after 120 mins by Kinase-Glo assay, IC50 = 0.25 μM. | 26081023 | |
| FDC-P1 | Function assay | 48 hrs | Inhibition of mouse GM-CSF-stimulated cell proliferation of growth factor dependent mouse FDC-P1 cells expressing human FMS after 48 hrs by resazurin dye reduction assay, IC50 = 0.2 μM. | 20156689 | |
| A375 | Toxicity assay | 72 hrs | Toxicity against human A375 cells after 72 hrs by cell titer-blue assay, IC50 = 0.18 μM. | 19654408 | |
| FDC-P1 | Function assay | 48 hrs | Inhibition of human FMS expressed in growth factor dependent mouse FDC-P1 cells assessed as inhibition of FMS-mediated cell proliferation in presence human CSF1 after 48 hrs by resazurin dye reduction assay, IC50 = 0.142 μM. | 20156689 | |
| Sf9 | Function assay | 90 mins | Inhibition of recombinant GST-tagged Aurora-A kinase domain (S123 to S401) (unknown origin) expressed in insect Sf9 cells using tetra(LRRASLG) peptide as substrate after 90 mins by Kinase-Glo assay, IC50 = 0.08 μM. | 26081023 | |
| MOLM-13 | Function assay | 72 hrs | Inhibition of FLT3 ITD heterozygous mutant in human MOLM-13 cells assessed as cell growth inhibition after 72 hrs by MTS assay, GI50 = 0.055 μM. | 26081023 | |
| MV4-11 | Function assay | 72 hrs | Inhibition of FLT3 ITD homozygous mutant in human MV4-11 cells assessed as cell growth inhibition after 72 hrs by MTS assay, GI50 = 0.038 μM. | 26081023 | |
| Sf9 | Function assay | 4 hrs | Inhibition of wild type GST-tagged FLT3 kinase domain (Y567 to S993) (unknown origin) expressed in baculovirus infected insect Sf9 cells using Her2 peptide as substrate after 4 hrs by Kinase-Glo assay, IC50 = 0.037 μM. | 26081023 | |
| RS4-11 | Function assay | 2 hrs | Inhibition of FLT3 autophosphorylation in human RS4-11 cells after 2 hrs by electrochemiluminescence assay, IC50 = 0.015 μM. | 19654408 | |
| RS4-11 | Function assay | 2 hrs | Inhibition of FLT3 ITD mutant autophosphorylation in human RS4-11 cells after 2 hrs by electrochemiluminescence assay, IC50 = 0.013 μM. | 19654408 | |
| MV4-11 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human MV4-11 cells after 72 hrs by cell titer-blue assay, IC50 = 0.012 μM. | 19654408 | |
| MOLM13 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human MOLM13 cells after 72 hrs by MTS assay, IC50 = 0.0047 μM. | 29350920 | |
| EOL-1 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human EOL-1 cells after 72 hrs by MTS assay, IC50 = 0.0038 μM. | 29350920 | |
| D-336MG | Growth Inhibition Assay | Inhibition of human D-336MG cell growth in a cell viability assay, IC50 = 0.08754 μM. | SANGER | ||
| HCC1395 | Growth Inhibition Assay | Inhibition of human HCC1395 cell growth in a cell viability assay, IC50 = 0.08428 μM. | SANGER | ||
| MES-SA | Growth Inhibition Assay | Inhibition of human MES-SA cell growth in a cell viability assay, IC50 = 0.07544 μM. | SANGER | ||
| NCI-H1755 | Growth Inhibition Assay | Inhibition of human NCI-H1755 cell growth in a cell viability assay, IC50 = 0.06273 μM. | SANGER | ||
| KASUMI-1 | Growth Inhibition Assay | Inhibition of human KASUMI-1 cell growth in a cell viability assay, IC50 = 0.06016 μM. | SANGER | ||
| EoL-1-cell | Growth Inhibition Assay | Inhibition of human EoL-1-cell cell growth in a cell viability assay, IC50 = 0.05208 μM. | SANGER | ||
| SW982 | Growth Inhibition Assay | Inhibition of human SW982 cell growth in a cell viability assay, IC50 = 0.04558 μM. | SANGER | ||
| CGTH-W-1 | Growth Inhibition Assay | Inhibition of human CGTH-W-1 cell growth in a cell viability assay, IC50 = 0.04265 μM. | SANGER | ||
| NKM-1 | Growth Inhibition Assay | Inhibition of human NKM-1 cell growth in a cell viability assay, IC50 = 0.03942 μM. | SANGER | ||
| MV-4-11 | Growth Inhibition Assay | Inhibition of human MV-4-11 cell growth in a cell viability assay, IC50 = 0.01983 μM. | SANGER | ||
| SN12C | Function assay | Identifying Small Molecule Inhibitors of Pancreatic Cancer Stem Cells (SN12C, Adherent), Potency = 1.6626 μM. | ChEMBL | ||
| Rh18 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells | 29435139 | ||
| NB1643 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells | 29435139 | ||
| MG 63 (6-TG R) | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 29435139 | ||
| OHS-50 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 29435139 | ||
| Rh18 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 29435139 | ||
| LAN-5 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 29435139 | ||
| SK-N-SH | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 29435139 | ||
| Saos-2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 29435139 | ||
| U-2 OS | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 29435139 | ||
| SK-N-MC | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 29435139 | ||
| A673 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 29435139 | ||
| SJ-GBM2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 29435139 | ||
| BAF3 | Antiproliferative assay | Antiproliferative activity against mouse BAF3 cells transformed with ZNF198-FGFR1 construct, IC50 = 0.2 μM. | 21936542 | ||
| CHP-212 | Growth Inhibition Assay | Inhibition of human CHP-212 cell growth in a cell viability assay, IC50 = 0.08773 μM. | SANGER | ||
| KM12 | Growth Inhibition Assay | Inhibition of human KM12 cell growth in a cell viability assay, IC50 = 0.09275 μM. | SANGER | ||
| A204 | Growth Inhibition Assay | Inhibition of human A204 cell growth in a cell viability assay, IC50 = 0.10052 μM. | SANGER | ||
| CAL-51 | Growth Inhibition Assay | Inhibition of human CAL-51 cell growth in a cell viability assay, IC50 = 0.10709 μM. | SANGER | ||
| NALM-6 | Growth Inhibition Assay | Inhibition of human NALM-6 cell growth in a cell viability assay, IC50 = 0.10803 μM. | SANGER | ||
| NCI-H2342 | Growth Inhibition Assay | Inhibition of human NCI-H2342 cell growth in a cell viability assay, IC50 = 0.10881 μM. | SANGER | ||
| MONO-MAC-6 | Growth Inhibition Assay | Inhibition of human MONO-MAC-6 cell growth in a cell viability assay, IC50 = 0.11136 μM. | SANGER | ||
| A431 | Growth Inhibition Assay | Inhibition of human A431 cell growth in a cell viability assay, IC50 = 0.11216 μM. | SANGER | ||
| LC-2-ad | Growth Inhibition Assay | Inhibition of human LC-2-ad cell growth in a cell viability assay, IC50 = 0.11345 μM. | SANGER | ||
| NCI-H650 | Growth Inhibition Assay | Inhibition of human NCI-H650 cell growth in a cell viability assay, IC50 = 0.11708 μM. | SANGER | ||
| KGN | Growth Inhibition Assay | Inhibition of human KGN cell growth in a cell viability assay, IC50 = 0.11741 μM. | SANGER | ||
| A427 | Growth Inhibition Assay | Inhibition of human A427 cell growth in a cell viability assay, IC50 = 0.11918 μM. | SANGER | ||
| 769-P | Growth Inhibition Assay | Inhibition of human 769-P cell growth in a cell viability assay, IC50 = 0.12082 μM. | SANGER | ||
| EFO-21 | Growth Inhibition Assay | Inhibition of human EFO-21 cell growth in a cell viability assay, IC50 = 0.12972 μM. | SANGER | ||
| KS-1 | Growth Inhibition Assay | Inhibition of human KS-1 cell growth in a cell viability assay, IC50 = 0.13006 μM. | SANGER | ||
| SNU-449 | Growth Inhibition Assay | Inhibition of human SNU-449 cell growth in a cell viability assay, IC50 = 0.1317 μM. | SANGER | ||
| SW1710 | Growth Inhibition Assay | Inhibition of human SW1710 cell growth in a cell viability assay, IC50 = 0.13316 μM. | SANGER | ||
| ABC-1 | Growth Inhibition Assay | Inhibition of human ABC-1 cell growth in a cell viability assay, IC50 = 0.13415 μM. | SANGER | ||
| NY | Growth Inhibition Assay | Inhibition of human NY cell growth in a cell viability assay, IC50 = 0.13748 μM. | SANGER | ||
| SNU-387 | Growth Inhibition Assay | Inhibition of human SNU-387 cell growth in a cell viability assay, IC50 = 0.13872 μM. | SANGER | ||
| H4 | Growth Inhibition Assay | Inhibition of human H4 cell growth in a cell viability assay, IC50 = 0.13963 μM. | SANGER | ||
| ALL-PO | Growth Inhibition Assay | Inhibition of human ALL-PO cell growth in a cell viability assay, IC50 = 0.14546 μM. | SANGER | ||
| HuO-3N1 | Growth Inhibition Assay | Inhibition of human HuO-3N1 cell growth in a cell viability assay, IC50 = 0.15463 μM. | SANGER | ||
| LB1047-RCC | Growth Inhibition Assay | Inhibition of human LB1047-RCC cell growth in a cell viability assay, IC50 = 0.15487 μM. | SANGER | ||
| HT-1080 | Growth Inhibition Assay | Inhibition of human HT-1080 cell growth in a cell viability assay, IC50 = 0.15982 μM. | SANGER | ||
| PANC-03-27 | Growth Inhibition Assay | Inhibition of human PANC-03-27 cell growth in a cell viability assay, IC50 = 0.1602 μM. | SANGER | ||
| MG-63 | Growth Inhibition Assay | Inhibition of human MG-63 cell growth in a cell viability assay, IC50 = 0.16437 μM. | SANGER | ||
| TCCSUP | Growth Inhibition Assay | Inhibition of human TCCSUP cell growth in a cell viability assay, IC50 = 0.16469 μM. | SANGER | ||
| KYSE-270 | Growth Inhibition Assay | Inhibition of human KYSE-270 cell growth in a cell viability assay, IC50 = 0.16778 μM. | SANGER | ||
| GDM-1 | Growth Inhibition Assay | Inhibition of human GDM-1 cell growth in a cell viability assay, IC50 = 0.17262 μM. | SANGER | ||
| HUTU-80 | Growth Inhibition Assay | Inhibition of human HUTU-80 cell growth in a cell viability assay, IC50 = 0.17279 μM. | SANGER | ||
| AGS | Growth Inhibition Assay | Inhibition of human AGS cell growth in a cell viability assay, IC50 = 0.17352 μM. | SANGER | ||
| MFH-ino | Growth Inhibition Assay | Inhibition of human MFH-ino cell growth in a cell viability assay, IC50 = 0.17455 μM. | SANGER | ||
| HuCCT1 | Growth Inhibition Assay | Inhibition of human HuCCT1 cell growth in a cell viability assay, IC50 = 0.17856 μM. | SANGER | ||
| HOP-62 | Growth Inhibition Assay | Inhibition of human HOP-62 cell growth in a cell viability assay, IC50 = 0.18073 μM. | SANGER | ||
| CAS-1 | Growth Inhibition Assay | Inhibition of human CAS-1 cell growth in a cell viability assay, IC50 = 0.18165 μM. | SANGER | ||
| PA-1 | Growth Inhibition Assay | Inhibition of human PA-1 cell growth in a cell viability assay, IC50 = 0.18499 μM. | SANGER | ||
| T98G | Growth Inhibition Assay | Inhibition of human T98G cell growth in a cell viability assay, IC50 = 0.18995 μM. | SANGER | ||
| GI-ME-N | Growth Inhibition Assay | Inhibition of human GI-ME-N cell growth in a cell viability assay, IC50 = 0.19475 μM. | SANGER | ||
| YKG-1 | Growth Inhibition Assay | Inhibition of human YKG-1 cell growth in a cell viability assay, IC50 = 0.19568 μM. | SANGER | ||
| U031 | Growth Inhibition Assay | Inhibition of human U031 cell growth in a cell viability assay, IC50 = 0.19698 μM. | SANGER | ||
| 8-MG-BA | Growth Inhibition Assay | Inhibition of human 8-MG-BA cell growth in a cell viability assay, IC50 = 0.1981 μM. | SANGER | ||
| G-402 | Growth Inhibition Assay | Inhibition of human G-402 cell growth in a cell viability assay, IC50 = 0.20253 μM. | SANGER | ||
| G-361 | Growth Inhibition Assay | Inhibition of human G-361 cell growth in a cell viability assay, IC50 = 0.20853 μM. | SANGER | ||
| CAL-54 | Growth Inhibition Assay | Inhibition of human CAL-54 cell growth in a cell viability assay, IC50 = 0.20859 μM. | SANGER | ||
| NTERA-S-cl-D1 | Growth Inhibition Assay | Inhibition of human NTERA-S-cl-D1 cell growth in a cell viability assay, IC50 = 0.20895 μM. | SANGER | ||
| NCI-H810 | Growth Inhibition Assay | Inhibition of human NCI-H810 cell growth in a cell viability assay, IC50 = 0.21027 μM. | SANGER | ||
| CAL-120 | Growth Inhibition Assay | Inhibition of human CAL-120 cell growth in a cell viability assay, IC50 = 0.21061 μM. | SANGER | ||
| EFM-19 | Growth Inhibition Assay | Inhibition of human EFM-19 cell growth in a cell viability assay, IC50 = 0.21213 μM. | SANGER | ||
| LCLC-103H | Growth Inhibition Assay | Inhibition of human LCLC-103H cell growth in a cell viability assay, IC50 = 0.21496 μM. | SANGER | ||
| CAKI-1 | Growth Inhibition Assay | Inhibition of human CAKI-1 cell growth in a cell viability assay, IC50 = 0.21505 μM. | SANGER | ||
| G-401 | Growth Inhibition Assay | Inhibition of human G-401 cell growth in a cell viability assay, IC50 = 0.22339 μM. | SANGER | ||
| NMC-G1 | Growth Inhibition Assay | Inhibition of human NMC-G1 cell growth in a cell viability assay, IC50 = 0.22359 μM. | SANGER | ||
| NCI-H2030 | Growth Inhibition Assay | Inhibition of human NCI-H2030 cell growth in a cell viability assay, IC50 = 0.23006 μM. | SANGER | ||
| HCT-116 | Growth Inhibition Assay | Inhibition of human HCT-116 cell growth in a cell viability assay, IC50 = 0.23568 μM. | SANGER | ||
| SNU-423 | Growth Inhibition Assay | Inhibition of human SNU-423 cell growth in a cell viability assay, IC50 = 0.23657 μM. | SANGER | ||
| SCC-4 | Growth Inhibition Assay | Inhibition of human SCC-4 cell growth in a cell viability assay, IC50 = 0.23967 μM. | SANGER | ||
| SF126 | Growth Inhibition Assay | Inhibition of human SF126 cell growth in a cell viability assay, IC50 = 0.24731 μM. | SANGER | ||
| HSC-2 | Growth Inhibition Assay | Inhibition of human HSC-2 cell growth in a cell viability assay, IC50 = 0.24734 μM. | SANGER | ||
| VA-ES-BJ | Growth Inhibition Assay | Inhibition of human VA-ES-BJ cell growth in a cell viability assay, IC50 = 0.24883 μM. | SANGER | ||
| MHH-ES-1 | Growth Inhibition Assay | Inhibition of human MHH-ES-1 cell growth in a cell viability assay, IC50 = 0.2494 μM. | SANGER | ||
| D-247MG | Growth Inhibition Assay | Inhibition of human D-247MG cell growth in a cell viability assay, IC50 = 0.25013 μM. | SANGER | ||
| CCF-STTG1 | Growth Inhibition Assay | Inhibition of human CCF-STTG1 cell growth in a cell viability assay, IC50 = 0.25335 μM. | SANGER | ||
| BFTC-905 | Growth Inhibition Assay | Inhibition of human BFTC-905 cell growth in a cell viability assay, IC50 = 0.25458 μM. | SANGER | ||
| YT | Growth Inhibition Assay | Inhibition of human YT cell growth in a cell viability assay, IC50 = 0.26282 μM. | SANGER | ||
| KYSE-150 | Growth Inhibition Assay | Inhibition of human KYSE-150 cell growth in a cell viability assay, IC50 = 0.26282 μM. | SANGER | ||
| NCI-H28 | Growth Inhibition Assay | Inhibition of human NCI-H28 cell growth in a cell viability assay, IC50 = 0.26585 μM. | SANGER | ||
| MC-IXC | Growth Inhibition Assay | Inhibition of human MC-IXC cell growth in a cell viability assay, IC50 = 0.26629 μM. | SANGER | ||
| SW48 | Growth Inhibition Assay | Inhibition of human SW48 cell growth in a cell viability assay, IC50 = 0.2668 μM. | SANGER | ||
| SF295 | Growth Inhibition Assay | Inhibition of human SF295 cell growth in a cell viability assay, IC50 = 0.27257 μM. | SANGER | ||
| 8505C | Growth Inhibition Assay | Inhibition of human 8505C cell growth in a cell viability assay, IC50 = 0.27604 μM. | SANGER | ||
| ONS-76 | Growth Inhibition Assay | Inhibition of human ONS-76 cell growth in a cell viability assay, IC50 = 0.27841 μM. | SANGER | ||
| CAL-12T | Growth Inhibition Assay | Inhibition of human CAL-12T cell growth in a cell viability assay, IC50 = 0.28001 μM. | SANGER | ||
| MDA-MB-231 | Growth Inhibition Assay | Inhibition of human MDA-MB-231 cell growth in a cell viability assay, IC50 = 0.28101 μM. | SANGER | ||
| GCIY | Growth Inhibition Assay | Inhibition of human GCIY cell growth in a cell viability assay, IC50 = 0.28692 μM. | SANGER | ||
| DoTc2-4510 | Growth Inhibition Assay | Inhibition of human DoTc2-4510 cell growth in a cell viability assay, IC50 = 0.29002 μM. | SANGER | ||
| A172 | Growth Inhibition Assay | Inhibition of human A172 cell growth in a cell viability assay, IC50 = 0.2915 μM. | SANGER | ||
| BCPAP | Growth Inhibition Assay | Inhibition of human BCPAP cell growth in a cell viability assay, IC50 = 0.29879 μM. | SANGER | ||
| LB831-BLC | Growth Inhibition Assay | Inhibition of human LB831-BLC cell growth in a cell viability assay, IC50 = 0.29946 μM. | SANGER | ||
| COLO-792 | Growth Inhibition Assay | Inhibition of human COLO-792 cell growth in a cell viability assay, IC50 = 0.29972 μM. | SANGER | ||
| BFTC-909 | Growth Inhibition Assay | Inhibition of human BFTC-909 cell growth in a cell viability assay, IC50 = 0.3107 μM. | SANGER | ||
| KYSE-410 | Growth Inhibition Assay | Inhibition of human KYSE-410 cell growth in a cell viability assay, IC50 = 0.31254 μM. | SANGER | ||
| EW-16 | Growth Inhibition Assay | Inhibition of human EW-16 cell growth in a cell viability assay, IC50 = 0.3143 μM. | SANGER | ||
| SK-MES-1 | Growth Inhibition Assay | Inhibition of human SK-MES-1 cell growth in a cell viability assay, IC50 = 0.31485 μM. | SANGER | ||
| DU-145 | Growth Inhibition Assay | Inhibition of human DU-145 cell growth in a cell viability assay, IC50 = 0.31889 μM. | SANGER | ||
| GI-1 | Growth Inhibition Assay | Inhibition of human GI-1 cell growth in a cell viability assay, IC50 = 0.31902 μM. | SANGER | ||
| AN3-CA | Growth Inhibition Assay | Inhibition of human AN3-CA cell growth in a cell viability assay, IC50 = 0.32198 μM. | SANGER | ||
| EW-18 | Growth Inhibition Assay | Inhibition of human EW-18 cell growth in a cell viability assay, IC50 = 0.32233 μM. | SANGER | ||
| NCI-H2122 | Growth Inhibition Assay | Inhibition of human NCI-H2122 cell growth in a cell viability assay, IC50 = 0.32285 μM. | SANGER | ||
| BB30-HNC | Growth Inhibition Assay | Inhibition of human BB30-HNC cell growth in a cell viability assay, IC50 = 0.32367 μM. | SANGER | ||
| DMS-273 | Growth Inhibition Assay | Inhibition of human DMS-273 cell growth in a cell viability assay, IC50 = 0.32388 μM. | SANGER | ||
| SK-UT-1 | Growth Inhibition Assay | Inhibition of human SK-UT-1 cell growth in a cell viability assay, IC50 = 0.32952 μM. | SANGER | ||
| LXF-289 | Growth Inhibition Assay | Inhibition of human LXF-289 cell growth in a cell viability assay, IC50 = 0.32965 μM. | SANGER | ||
| NCI-H1792 | Growth Inhibition Assay | Inhibition of human NCI-H1792 cell growth in a cell viability assay, IC50 = 0.33096 μM. | SANGER | ||
| ACHN | Growth Inhibition Assay | Inhibition of human ACHN cell growth in a cell viability assay, IC50 = 0.33117 μM. | SANGER | ||
| D-392MG | Growth Inhibition Assay | Inhibition of human D-392MG cell growth in a cell viability assay, IC50 = 0.3312 μM. | SANGER | ||
| MCF7 | Growth Inhibition Assay | Inhibition of human MCF7 cell growth in a cell viability assay, IC50 = 0.33274 μM. | SANGER | ||
| HCT-15 | Growth Inhibition Assay | Inhibition of human HCT-15 cell growth in a cell viability assay, IC50 = 0.33432 μM. | SANGER | ||
| OS-RC-2 | Growth Inhibition Assay | Inhibition of human OS-RC-2 cell growth in a cell viability assay, IC50 = 0.33512 μM. | SANGER | ||
| NCI-H358 | Growth Inhibition Assay | Inhibition of human NCI-H358 cell growth in a cell viability assay, IC50 = 0.33551 μM. | SANGER | ||
| HLE | Growth Inhibition Assay | Inhibition of human HLE cell growth in a cell viability assay, IC50 = 0.33752 μM. | SANGER | ||
| SW1088 | Growth Inhibition Assay | Inhibition of human SW1088 cell growth in a cell viability assay, IC50 = 0.33797 μM. | SANGER | ||
| MRK-nu-1 | Growth Inhibition Assay | Inhibition of human MRK-nu-1 cell growth in a cell viability assay, IC50 = 0.3396 μM. | SANGER | ||
| C-4-II | Growth Inhibition Assay | Inhibition of human C-4-II cell growth in a cell viability assay, IC50 = 0.34889 μM. | SANGER | ||
| ST486 | Growth Inhibition Assay | Inhibition of human ST486 cell growth in a cell viability assay, IC50 = 0.34939 μM. | SANGER | ||
| NCI-H2405 | Growth Inhibition Assay | Inhibition of human NCI-H2405 cell growth in a cell viability assay, IC50 = 0.35115 μM. | SANGER | ||
| SK-LMS-1 | Growth Inhibition Assay | Inhibition of human SK-LMS-1 cell growth in a cell viability assay, IC50 = 0.35335 μM. | SANGER | ||
| PANC-10-05 | Growth Inhibition Assay | Inhibition of human PANC-10-05 cell growth in a cell viability assay, IC50 = 0.35633 μM. | SANGER | ||
| K5 | Growth Inhibition Assay | Inhibition of human K5 cell growth in a cell viability assay, IC50 = 0.36149 μM. | SANGER | ||
| SR | Growth Inhibition Assay | Inhibition of human SR cell growth in a cell viability assay, IC50 = 0.36571 μM. | SANGER | ||
| Calu-3 | Growth Inhibition Assay | Inhibition of human Calu-3 cell growth in a cell viability assay, IC50 = 0.36825 μM. | SANGER | ||
| VMRC-RCZ | Growth Inhibition Assay | Inhibition of human VMRC-RCZ cell growth in a cell viability assay, IC50 = 0.36935 μM. | SANGER | ||
| COR-L105 | Growth Inhibition Assay | Inhibition of human COR-L105 cell growth in a cell viability assay, IC50 = 0.37071 μM. | SANGER | ||
| ETK-1 | Growth Inhibition Assay | Inhibition of human ETK-1 cell growth in a cell viability assay, IC50 = 0.37693 μM. | SANGER | ||
| GT3TKB | Growth Inhibition Assay | Inhibition of human GT3TKB cell growth in a cell viability assay, IC50 = 0.38043 μM. | SANGER | ||
| PF-382 | Growth Inhibition Assay | Inhibition of human PF-382 cell growth in a cell viability assay, IC50 = 0.38756 μM. | SANGER | ||
| HT-144 | Growth Inhibition Assay | Inhibition of human HT-144 cell growth in a cell viability assay, IC50 = 0.38948 μM. | SANGER | ||
| TK10 | Growth Inhibition Assay | Inhibition of human TK10 cell growth in a cell viability assay, IC50 = 0.39144 μM. | SANGER | ||
| IGR-1 | Growth Inhibition Assay | Inhibition of human IGR-1 cell growth in a cell viability assay, IC50 = 0.39369 μM. | SANGER | ||
| SF268 | Growth Inhibition Assay | Inhibition of human SF268 cell growth in a cell viability assay, IC50 = 0.39381 μM. | SANGER | ||
| L-540 | Growth Inhibition Assay | Inhibition of human L-540 cell growth in a cell viability assay, IC50 = 0.39454 μM. | SANGER | ||
| SK-MEL-30 | Growth Inhibition Assay | Inhibition of human SK-MEL-30 cell growth in a cell viability assay, IC50 = 0.39913 μM. | SANGER | ||
| KYSE-520 | Growth Inhibition Assay | Inhibition of human KYSE-520 cell growth in a cell viability assay, IC50 = 0.40238 μM. | SANGER | ||
| RXF393 | Growth Inhibition Assay | Inhibition of human RXF393 cell growth in a cell viability assay, IC50 = 0.40604 μM. | SANGER | ||
| A704 | Growth Inhibition Assay | Inhibition of human A704 cell growth in a cell viability assay, IC50 = 0.40917 μM. | SANGER | ||
| HCE-4 | Growth Inhibition Assay | Inhibition of human HCE-4 cell growth in a cell viability assay, IC50 = 0.4101 μM. | SANGER | ||
| SW780 | Growth Inhibition Assay | Inhibition of human SW780 cell growth in a cell viability assay, IC50 = 0.41142 μM. | SANGER | ||
| TUR | Growth Inhibition Assay | Inhibition of human TUR cell growth in a cell viability assay, IC50 = 0.41374 μM. | SANGER | ||
| D-263MG | Growth Inhibition Assay | Inhibition of human D-263MG cell growth in a cell viability assay, IC50 = 0.41413 μM. | SANGER | ||
| NCI-H1563 | Growth Inhibition Assay | Inhibition of human NCI-H1563 cell growth in a cell viability assay, IC50 = 0.41484 μM. | SANGER | ||
| MZ1-PC | Growth Inhibition Assay | Inhibition of human MZ1-PC cell growth in a cell viability assay, IC50 = 0.41783 μM. | SANGER | ||
| MKN45 | Growth Inhibition Assay | Inhibition of human MKN45 cell growth in a cell viability assay, IC50 = 0.41931 μM. | SANGER | ||
| MDA-MB-157 | Growth Inhibition Assay | Inhibition of human MDA-MB-157 cell growth in a cell viability assay, IC50 = 0.42015 μM. | SANGER | ||
| RKO | Growth Inhibition Assay | Inhibition of human RKO cell growth in a cell viability assay, IC50 = 0.42017 μM. | SANGER | ||
| NCI-H522 | Growth Inhibition Assay | Inhibition of human NCI-H522 cell growth in a cell viability assay, IC50 = 0.423 μM. | SANGER | ||
| ECC12 | Growth Inhibition Assay | Inhibition of human ECC12 cell growth in a cell viability assay, IC50 = 0.42923 μM. | SANGER | ||
| COLO-205 | Growth Inhibition Assay | Inhibition of human COLO-205 cell growth in a cell viability assay, IC50 = 0.43222 μM. | SANGER | ||
| EW-13 | Growth Inhibition Assay | Inhibition of human EW-13 cell growth in a cell viability assay, IC50 = 0.43548 μM. | SANGER | ||
| CAL-39 | Growth Inhibition Assay | Inhibition of human CAL-39 cell growth in a cell viability assay, IC50 = 0.43719 μM. | SANGER | ||
| MPP-89 | Growth Inhibition Assay | Inhibition of human MPP-89 cell growth in a cell viability assay, IC50 = 0.43945 μM. | SANGER | ||
| SK-LU-1 | Growth Inhibition Assay | Inhibition of human SK-LU-1 cell growth in a cell viability assay, IC50 = 0.43985 μM. | SANGER | ||
| HuO9 | Growth Inhibition Assay | Inhibition of human HuO9 cell growth in a cell viability assay, IC50 = 0.44135 μM. | SANGER | ||
| NCI-H2170 | Growth Inhibition Assay | Inhibition of human NCI-H2170 cell growth in a cell viability assay, IC50 = 0.44353 μM. | SANGER | ||
| HOS | Growth Inhibition Assay | Inhibition of human HOS cell growth in a cell viability assay, IC50 = 0.45888 μM. | SANGER | ||
| CCRF-CEM | Growth Inhibition Assay | Inhibition of human CCRF-CEM cell growth in a cell viability assay, IC50 = 0.47081 μM. | SANGER | ||
| COLO-680N | Growth Inhibition Assay | Inhibition of human COLO-680N cell growth in a cell viability assay, IC50 = 0.47106 μM. | SANGER | ||
| 786-0 | Growth Inhibition Assay | Inhibition of human 786-0 cell growth in a cell viability assay, IC50 = 0.47344 μM. | SANGER | ||
| EFE-184 | Growth Inhibition Assay | Inhibition of human EFE-184 cell growth in a cell viability assay, IC50 = 0.47346 μM. | SANGER | ||
| A2780 | Growth Inhibition Assay | Inhibition of human A2780 cell growth in a cell viability assay, IC50 = 0.47503 μM. | SANGER | ||
| A498 | Growth Inhibition Assay | Inhibition of human A498 cell growth in a cell viability assay, IC50 = 0.47693 μM. | SANGER | ||
| KYSE-180 | Growth Inhibition Assay | Inhibition of human KYSE-180 cell growth in a cell viability assay, IC50 = 0.47825 μM. | SANGER | ||
| SIG-M5 | Growth Inhibition Assay | Inhibition of human SIG-M5 cell growth in a cell viability assay, IC50 = 0.48299 μM. | SANGER | ||
| NCI-H2009 | Growth Inhibition Assay | Inhibition of human NCI-H2009 cell growth in a cell viability assay, IC50 = 0.48689 μM. | SANGER | ||
| BC-3 | Growth Inhibition Assay | Inhibition of human BC-3 cell growth in a cell viability assay, IC50 = 0.48741 μM. | SANGER | ||
| MEL-JUSO | Growth Inhibition Assay | Inhibition of human MEL-JUSO cell growth in a cell viability assay, IC50 = 0.49214 μM. | SANGER | ||
| SH-4 | Growth Inhibition Assay | Inhibition of human SH-4 cell growth in a cell viability assay, IC50 = 0.49271 μM. | SANGER | ||
| SNG-M | Growth Inhibition Assay | Inhibition of human SNG-M cell growth in a cell viability assay, IC50 = 0.49283 μM. | SANGER | ||
| BxPC-3 | Growth Inhibition Assay | Inhibition of human BxPC-3 cell growth in a cell viability assay, IC50 = 0.49366 μM. | SANGER | ||
| HCC38 | Growth Inhibition Assay | Inhibition of human HCC38 cell growth in a cell viability assay, IC50 = 0.49828 μM. | SANGER | ||
| SK-HEP-1 | Growth Inhibition Assay | Inhibition of human SK-HEP-1 cell growth in a cell viability assay, IC50 = 0.51297 μM. | SANGER | ||
| REH | Growth Inhibition Assay | Inhibition of human REH cell growth in a cell viability assay, IC50 = 0.51334 μM. | SANGER | ||
| NCI-H1299 | Growth Inhibition Assay | Inhibition of human NCI-H1299 cell growth in a cell viability assay, IC50 = 0.51572 μM. | SANGER | ||
| SK-CO-1 | Growth Inhibition Assay | Inhibition of human SK-CO-1 cell growth in a cell viability assay, IC50 = 0.51849 μM. | SANGER | ||
| EFO-27 | Growth Inhibition Assay | Inhibition of human EFO-27 cell growth in a cell viability assay, IC50 = 0.52524 μM. | SANGER | ||
| A2058 | Growth Inhibition Assay | Inhibition of human A2058 cell growth in a cell viability assay, IC50 = 0.52844 μM. | SANGER | ||
| GCT | Growth Inhibition Assay | Inhibition of human GCT cell growth in a cell viability assay, IC50 = 0.52897 μM. | SANGER | ||
| EW-1 | Growth Inhibition Assay | Inhibition of human EW-1 cell growth in a cell viability assay, IC50 = 0.53155 μM. | SANGER | ||
| PC-14 | Growth Inhibition Assay | Inhibition of human PC-14 cell growth in a cell viability assay, IC50 = 0.53855 μM. | SANGER | ||
| KG-1 | Growth Inhibition Assay | Inhibition of human KG-1 cell growth in a cell viability assay, IC50 = 0.55419 μM. | SANGER | ||
| LU-99A | Growth Inhibition Assay | Inhibition of human LU-99A cell growth in a cell viability assay, IC50 = 0.55849 μM. | SANGER | ||
| DEL | Growth Inhibition Assay | Inhibition of human DEL cell growth in a cell viability assay, IC50 = 0.55898 μM. | SANGER | ||
| GB-1 | Growth Inhibition Assay | Inhibition of human GB-1 cell growth in a cell viability assay, IC50 = 0.56007 μM. | SANGER | ||
| A4-Fuk | Growth Inhibition Assay | Inhibition of human A4-Fuk cell growth in a cell viability assay, IC50 = 0.56048 μM. | SANGER | ||
| A375 | Growth Inhibition Assay | Inhibition of human A375 cell growth in a cell viability assay, IC50 = 0.56103 μM. | SANGER | ||
| CAL-85-1 | Growth Inhibition Assay | Inhibition of human CAL-85-1 cell growth in a cell viability assay, IC50 = 0.56518 μM. | SANGER | ||
| BC-1 | Growth Inhibition Assay | Inhibition of human BC-1 cell growth in a cell viability assay, IC50 = 0.56558 μM. | SANGER | ||
| SCC-15 | Growth Inhibition Assay | Inhibition of human SCC-15 cell growth in a cell viability assay, IC50 = 0.57407 μM. | SANGER | ||
| RPMI-8402 | Growth Inhibition Assay | Inhibition of human RPMI-8402 cell growth in a cell viability assay, IC50 = 0.57766 μM. | SANGER | ||
| OAW-42 | Growth Inhibition Assay | Inhibition of human OAW-42 cell growth in a cell viability assay, IC50 = 0.58091 μM. | SANGER | ||
| A101D | Growth Inhibition Assay | Inhibition of human A101D cell growth in a cell viability assay, IC50 = 0.58789 μM. | SANGER | ||
| RPMI-7951 | Growth Inhibition Assay | Inhibition of human RPMI-7951 cell growth in a cell viability assay, IC50 = 0.61123 μM. | SANGER | ||
| TE-12 | Growth Inhibition Assay | Inhibition of human TE-12 cell growth in a cell viability assay, IC50 = 0.61199 μM. | SANGER | ||
| P30-OHK | Growth Inhibition Assay | Inhibition of human P30-OHK cell growth in a cell viability assay, IC50 = 0.61246 μM. | SANGER | ||
| KP-4 | Growth Inhibition Assay | Inhibition of human KP-4 cell growth in a cell viability assay, IC50 = 0.61585 μM. | SANGER | ||
| U251 | Growth Inhibition Assay | Inhibition of human U251 cell growth in a cell viability assay, IC50 = 0.61621 μM. | SANGER | ||
| RS4-11 | Growth Inhibition Assay | Inhibition of human RS4-11 cell growth in a cell viability assay, IC50 = 0.62417 μM. | SANGER | ||
| CA46 | Growth Inhibition Assay | Inhibition of human CA46 cell growth in a cell viability assay, IC50 = 0.62885 μM. | SANGER | ||
| DOK | Growth Inhibition Assay | Inhibition of human DOK cell growth in a cell viability assay, IC50 = 0.6367 μM. | SANGER | ||
| NCI-H2126 | Growth Inhibition Assay | Inhibition of human NCI-H2126 cell growth in a cell viability assay, IC50 = 0.64325 μM. | SANGER | ||
| CaR-1 | Growth Inhibition Assay | Inhibition of human CaR-1 cell growth in a cell viability assay, IC50 = 0.64476 μM. | SANGER | ||
| ACN | Growth Inhibition Assay | Inhibition of human ACN cell growth in a cell viability assay, IC50 = 0.64832 μM. | SANGER | ||
| SUP-T1 | Growth Inhibition Assay | Inhibition of human SUP-T1 cell growth in a cell viability assay, IC50 = 0.65424 μM. | SANGER | ||
| KALS-1 | Growth Inhibition Assay | Inhibition of human KALS-1 cell growth in a cell viability assay, IC50 = 0.65903 μM. | SANGER | ||
| 697 | Growth Inhibition Assay | Inhibition of human 697 cell growth in a cell viability assay, IC50 = 0.67132 μM. | SANGER | ||
| NCI-H2087 | Growth Inhibition Assay | Inhibition of human NCI-H2087 cell growth in a cell viability assay, IC50 = 0.67782 μM. | SANGER | ||
| NCI-H1355 | Growth Inhibition Assay | Inhibition of human NCI-H1355 cell growth in a cell viability assay, IC50 = 0.67816 μM. | SANGER | ||
| EW-7 | Growth Inhibition Assay | Inhibition of human EW-7 cell growth in a cell viability assay, IC50 = 0.68195 μM. | SANGER | ||
| OVCAR-5 | Growth Inhibition Assay | Inhibition of human OVCAR-5 cell growth in a cell viability assay, IC50 = 0.69167 μM. | SANGER | ||
| HOP-92 | Growth Inhibition Assay | Inhibition of human HOP-92 cell growth in a cell viability assay, IC50 = 0.69865 μM. | SANGER | ||
| NCI-H2052 | Growth Inhibition Assay | Inhibition of human NCI-H2052 cell growth in a cell viability assay, IC50 = 0.69894 μM. | SANGER | ||
| NCI-H1703 | Growth Inhibition Assay | Inhibition of human NCI-H1703 cell growth in a cell viability assay, IC50 = 0.70473 μM. | SANGER | ||
| NCI-H719 | Growth Inhibition Assay | Inhibition of human NCI-H719 cell growth in a cell viability assay, IC50 = 0.70676 μM. | SANGER | ||
| MC116 | Growth Inhibition Assay | Inhibition of human MC116 cell growth in a cell viability assay, IC50 = 0.71581 μM. | SANGER | ||
| NCI-H526 | Growth Inhibition Assay | Inhibition of human NCI-H526 cell growth in a cell viability assay, IC50 = 0.71925 μM. | SANGER | ||
| MEL-HO | Growth Inhibition Assay | Inhibition of human MEL-HO cell growth in a cell viability assay, IC50 = 0.72664 μM. | SANGER | ||
| AM-38 | Growth Inhibition Assay | Inhibition of human AM-38 cell growth in a cell viability assay, IC50 = 0.72871 μM. | SANGER | ||
| SW1783 | Growth Inhibition Assay | Inhibition of human SW1783 cell growth in a cell viability assay, IC50 = 0.73337 μM. | SANGER | ||
| NB69 | Growth Inhibition Assay | Inhibition of human NB69 cell growth in a cell viability assay, IC50 = 0.73467 μM. | SANGER | ||
| VM-CUB-1 | Growth Inhibition Assay | Inhibition of human VM-CUB-1 cell growth in a cell viability assay, IC50 = 0.7367 μM. | SANGER | ||
| LCLC-97TM1 | Growth Inhibition Assay | Inhibition of human LCLC-97TM1 cell growth in a cell viability assay, IC50 = 0.75396 μM. | SANGER | ||
| NCCIT | Growth Inhibition Assay | Inhibition of human NCCIT cell growth in a cell viability assay, IC50 = 0.76775 μM. | SANGER | ||
| SNB75 | Growth Inhibition Assay | Inhibition of human SNB75 cell growth in a cell viability assay, IC50 = 0.77311 μM. | SANGER | ||
| NCI-H292 | Growth Inhibition Assay | Inhibition of human NCI-H292 cell growth in a cell viability assay, IC50 = 0.77393 μM. | SANGER | ||
| NCI-H1734 | Growth Inhibition Assay | Inhibition of human NCI-H1734 cell growth in a cell viability assay, IC50 = 0.77483 μM. | SANGER | ||
| KYSE-510 | Growth Inhibition Assay | Inhibition of human KYSE-510 cell growth in a cell viability assay, IC50 = 0.78539 μM. | SANGER | ||
| RL95-2 | Growth Inhibition Assay | Inhibition of human RL95-2 cell growth in a cell viability assay, IC50 = 0.79572 μM. | SANGER | ||
| ML-2 | Growth Inhibition Assay | Inhibition of human ML-2 cell growth in a cell viability assay, IC50 = 0.79859 μM. | SANGER | ||
| NCI-H1793 | Growth Inhibition Assay | Inhibition of human NCI-H1793 cell growth in a cell viability assay, IC50 = 0.80088 μM. | SANGER | ||
| LOUCY | Growth Inhibition Assay | Inhibition of human LOUCY cell growth in a cell viability assay, IC50 = 0.805 μM. | SANGER | ||
| KYSE-70 | Growth Inhibition Assay | Inhibition of human KYSE-70 cell growth in a cell viability assay, IC50 = 0.82041 μM. | SANGER | ||
| NB13 | Growth Inhibition Assay | Inhibition of human NB13 cell growth in a cell viability assay, IC50 = 0.82057 μM. | SANGER | ||
| A3-KAW | Growth Inhibition Assay | Inhibition of human A3-KAW cell growth in a cell viability assay, IC50 = 0.83993 μM. | SANGER | ||
| GR-ST | Growth Inhibition Assay | Inhibition of human GR-ST cell growth in a cell viability assay, IC50 = 0.87237 μM. | SANGER | ||
| SCC-9 | Growth Inhibition Assay | Inhibition of human SCC-9 cell growth in a cell viability assay, IC50 = 0.87286 μM. | SANGER | ||
| HCC1599 | Growth Inhibition Assay | Inhibition of human HCC1599 cell growth in a cell viability assay, IC50 = 0.8791 μM. | SANGER | ||
| MKN1 | Growth Inhibition Assay | Inhibition of human MKN1 cell growth in a cell viability assay, IC50 = 0.88412 μM. | SANGER | ||
| NCI-H1650 | Growth Inhibition Assay | Inhibition of human NCI-H1650 cell growth in a cell viability assay, IC50 = 0.88916 μM. | SANGER | ||
| LS-1034 | Growth Inhibition Assay | Inhibition of human LS-1034 cell growth in a cell viability assay, IC50 = 0.90528 μM. | SANGER | ||
| 639-V | Growth Inhibition Assay | Inhibition of human 639-V cell growth in a cell viability assay, IC50 = 0.92063 μM. | SANGER | ||
| BL-41 | Growth Inhibition Assay | Inhibition of human BL-41 cell growth in a cell viability assay, IC50 = 0.92539 μM. | SANGER | ||
| HT-1376 | Growth Inhibition Assay | Inhibition of human HT-1376 cell growth in a cell viability assay, IC50 = 0.92918 μM. | SANGER | ||
| CAL-62 | Growth Inhibition Assay | Inhibition of human CAL-62 cell growth in a cell viability assay, IC50 = 0.93235 μM. | SANGER | ||
| DBTRG-05MG | Growth Inhibition Assay | Inhibition of human DBTRG-05MG cell growth in a cell viability assay, IC50 = 0.94197 μM. | SANGER | ||
| SW872 | Growth Inhibition Assay | Inhibition of human SW872 cell growth in a cell viability assay, IC50 = 0.94459 μM. | SANGER | ||
| RT-112 | Growth Inhibition Assay | Inhibition of human RT-112 cell growth in a cell viability assay, IC50 = 0.97483 μM. | SANGER | ||
| HT-29 | Growth Inhibition Assay | Inhibition of human HT-29 cell growth in a cell viability assay, IC50 = 0.97996 μM. | SANGER | ||
| U-266 | Growth Inhibition Assay | Inhibition of human U-266 cell growth in a cell viability assay, IC50 = 0.98302 μM. | SANGER | ||
| HEL | Growth Inhibition Assay | Inhibition of human HEL cell growth in a cell viability assay, IC50 = 0.98517 μM. | SANGER | ||
| LB2241-RCC | Growth Inhibition Assay | Inhibition of human LB2241-RCC cell growth in a cell viability assay, IC50 = 0.98707 μM. | SANGER | ||
| TE-441-T | Growth Inhibition Assay | Inhibition of human TE-441-T cell growth in a cell viability assay, IC50 = 0.99434 μM. | SANGER | ||
| UM-UC-3 | Growth Inhibition Assay | Inhibition of human UM-UC-3 cell growth in a cell viability assay, IC50 = 1.00689 μM. | SANGER | ||
| DSH1 | Growth Inhibition Assay | Inhibition of human DSH1 cell growth in a cell viability assay, IC50 = 1.02389 μM. | SANGER | ||
| SCC-25 | Growth Inhibition Assay | Inhibition of human SCC-25 cell growth in a cell viability assay, IC50 = 1.04887 μM. | SANGER | ||
| OAW-28 | Growth Inhibition Assay | Inhibition of human OAW-28 cell growth in a cell viability assay, IC50 = 1.0569 μM. | SANGER | ||
| TE-11 | Growth Inhibition Assay | Inhibition of human TE-11 cell growth in a cell viability assay, IC50 = 1.07154 μM. | SANGER | ||
| RD | Growth Inhibition Assay | Inhibition of human RD cell growth in a cell viability assay, IC50 = 1.07208 μM. | SANGER | ||
| ESS-1 | Growth Inhibition Assay | Inhibition of human ESS-1 cell growth in a cell viability assay, IC50 = 1.07618 μM. | SANGER | ||
| CMK | Growth Inhibition Assay | Inhibition of human CMK cell growth in a cell viability assay, IC50 = 1.09082 μM. | SANGER | ||
| KURAMOCHI | Growth Inhibition Assay | Inhibition of human KURAMOCHI cell growth in a cell viability assay, IC50 = 1.10935 μM. | SANGER | ||
| KU812 | Growth Inhibition Assay | Inhibition of human KU812 cell growth in a cell viability assay, IC50 = 1.11164 μM. | SANGER | ||
| COLO-668 | Growth Inhibition Assay | Inhibition of human COLO-668 cell growth in a cell viability assay, IC50 = 1.12232 μM. | SANGER | ||
| KYSE-140 | Growth Inhibition Assay | Inhibition of human KYSE-140 cell growth in a cell viability assay, IC50 = 1.14444 μM. | SANGER | ||
| NCI-H716 | Growth Inhibition Assay | Inhibition of human NCI-H716 cell growth in a cell viability assay, IC50 = 1.15487 μM. | SANGER | ||
| ES4 | Growth Inhibition Assay | Inhibition of human ES4 cell growth in a cell viability assay, IC50 = 1.16462 μM. | SANGER | ||
| SW626 | Growth Inhibition Assay | Inhibition of human SW626 cell growth in a cell viability assay, IC50 = 1.16813 μM. | SANGER | ||
| U-2-OS | Growth Inhibition Assay | Inhibition of human U-2-OS cell growth in a cell viability assay, IC50 = 1.16996 μM. | SANGER | ||
| HCC1569 | Growth Inhibition Assay | Inhibition of human HCC1569 cell growth in a cell viability assay, IC50 = 1.17018 μM. | SANGER | ||
| A673 | Growth Inhibition Assay | Inhibition of human A673 cell growth in a cell viability assay, IC50 = 1.17069 μM. | SANGER | ||
| GAMG | Growth Inhibition Assay | Inhibition of human GAMG cell growth in a cell viability assay, IC50 = 1.17866 μM. | SANGER | ||
| FADU | Growth Inhibition Assay | Inhibition of human FADU cell growth in a cell viability assay, IC50 = 1.18547 μM. | SANGER | ||
| MKN28 | Growth Inhibition Assay | Inhibition of human MKN28 cell growth in a cell viability assay, IC50 = 1.19816 μM. | SANGER | ||
| DB | Growth Inhibition Assay | Inhibition of human DB cell growth in a cell viability assay, IC50 = 1.21929 μM. | SANGER | ||
| ES8 | Growth Inhibition Assay | Inhibition of human ES8 cell growth in a cell viability assay, IC50 = 1.22304 μM. | SANGER | ||
| OVCAR-3 | Growth Inhibition Assay | Inhibition of human OVCAR-3 cell growth in a cell viability assay, IC50 = 1.22696 μM. | SANGER | ||
| SW954 | Growth Inhibition Assay | Inhibition of human SW954 cell growth in a cell viability assay, IC50 = 1.25911 μM. | SANGER | ||
| ECC4 | Growth Inhibition Assay | Inhibition of human ECC4 cell growth in a cell viability assay, IC50 = 1.26182 μM. | SANGER | ||
| SK-MEL-3 | Growth Inhibition Assay | Inhibition of human SK-MEL-3 cell growth in a cell viability assay, IC50 = 1.26372 μM. | SANGER | ||
| SBC-5 | Growth Inhibition Assay | Inhibition of human SBC-5 cell growth in a cell viability assay, IC50 = 1.27389 μM. | SANGER | ||
| TE-10 | Growth Inhibition Assay | Inhibition of human TE-10 cell growth in a cell viability assay, IC50 = 1.2814 μM. | SANGER | ||
| NCI-H630 | Growth Inhibition Assay | Inhibition of human NCI-H630 cell growth in a cell viability assay, IC50 = 1.28805 μM. | SANGER | ||
| EGI-1 | Growth Inhibition Assay | Inhibition of human EGI-1 cell growth in a cell viability assay, IC50 = 1.30089 μM. | SANGER | ||
| NCI-H1770 | Growth Inhibition Assay | Inhibition of human NCI-H1770 cell growth in a cell viability assay, IC50 = 1.31382 μM. | SANGER | ||
| ES5 | Growth Inhibition Assay | Inhibition of human ES5 cell growth in a cell viability assay, IC50 = 1.32981 μM. | SANGER | ||
| Daoy | Growth Inhibition Assay | Inhibition of human Daoy cell growth in a cell viability assay, IC50 = 1.3357 μM. | SANGER | ||
| OCUB-M | Growth Inhibition Assay | Inhibition of human OCUB-M cell growth in a cell viability assay, IC50 = 1.35915 μM. | SANGER | ||
| WSU-NHL | Growth Inhibition Assay | Inhibition of human WSU-NHL cell growth in a cell viability assay, IC50 = 1.39185 μM. | SANGER | ||
| M059J | Growth Inhibition Assay | Inhibition of human M059J cell growth in a cell viability assay, IC50 = 1.39231 μM. | SANGER | ||
| NCI-H69 | Growth Inhibition Assay | Inhibition of human NCI-H69 cell growth in a cell viability assay, IC50 = 1.39549 μM. | SANGER | ||
| NH-12 | Growth Inhibition Assay | Inhibition of human NH-12 cell growth in a cell viability assay, IC50 = 1.40262 μM. | SANGER | ||
| COLO-800 | Growth Inhibition Assay | Inhibition of human COLO-800 cell growth in a cell viability assay, IC50 = 1.4036 μM. | SANGER | ||
| NB6 | Growth Inhibition Assay | Inhibition of human NB6 cell growth in a cell viability assay, IC50 = 1.4446 μM. | SANGER | ||
| C3A | Growth Inhibition Assay | Inhibition of human C3A cell growth in a cell viability assay, IC50 = 1.44539 μM. | SANGER | ||
| BB65-RCC | Growth Inhibition Assay | Inhibition of human BB65-RCC cell growth in a cell viability assay, IC50 = 1.47436 μM. | SANGER | ||
| CTB-1 | Growth Inhibition Assay | Inhibition of human CTB-1 cell growth in a cell viability assay, IC50 = 1.486 μM. | SANGER | ||
| HCC1806 | Growth Inhibition Assay | Inhibition of human HCC1806 cell growth in a cell viability assay, IC50 = 1.53072 μM. | SANGER | ||
| TE-15 | Growth Inhibition Assay | Inhibition of human TE-15 cell growth in a cell viability assay, IC50 = 1.53748 μM. | SANGER | ||
| GMS-10 | Growth Inhibition Assay | Inhibition of human GMS-10 cell growth in a cell viability assay, IC50 = 1.53837 μM. | SANGER | ||
| ES7 | Growth Inhibition Assay | Inhibition of human ES7 cell growth in a cell viability assay, IC50 = 1.53848 μM. | SANGER | ||
| RO82-W-1 | Growth Inhibition Assay | Inhibition of human RO82-W-1 cell growth in a cell viability assay, IC50 = 1.54406 μM. | SANGER | ||
| NCI-H1522 | Growth Inhibition Assay | Inhibition of human NCI-H1522 cell growth in a cell viability assay, IC50 = 1.545 μM. | SANGER | ||
| IST-MES1 | Growth Inhibition Assay | Inhibition of human IST-MES1 cell growth in a cell viability assay, IC50 = 1.56074 μM. | SANGER | ||
| EM-2 | Growth Inhibition Assay | Inhibition of human EM-2 cell growth in a cell viability assay, IC50 = 1.56554 μM. | SANGER | ||
| NUGC-3 | Growth Inhibition Assay | Inhibition of human NUGC-3 cell growth in a cell viability assay, IC50 = 1.56928 μM. | SANGER | ||
| BOKU | Growth Inhibition Assay | Inhibition of human BOKU cell growth in a cell viability assay, IC50 = 1.5697 μM. | SANGER | ||
| DK-MG | Growth Inhibition Assay | Inhibition of human DK-MG cell growth in a cell viability assay, IC50 = 1.58048 μM. | SANGER | ||
| SW620 | Growth Inhibition Assay | Inhibition of human SW620 cell growth in a cell viability assay, IC50 = 1.61701 μM. | SANGER | ||
| NCI-H1693 | Growth Inhibition Assay | Inhibition of human NCI-H1693 cell growth in a cell viability assay, IC50 = 1.63492 μM. | SANGER | ||
| NCI-H838 | Growth Inhibition Assay | Inhibition of human NCI-H838 cell growth in a cell viability assay, IC50 = 1.63895 μM. | SANGER | ||
| HTC-C3 | Growth Inhibition Assay | Inhibition of human HTC-C3 cell growth in a cell viability assay, IC50 = 1.64035 μM. | SANGER | ||
| TE-6 | Growth Inhibition Assay | Inhibition of human TE-6 cell growth in a cell viability assay, IC50 = 1.64833 μM. | SANGER | ||
| QIMR-WIL | Growth Inhibition Assay | Inhibition of human QIMR-WIL cell growth in a cell viability assay, IC50 = 1.65364 μM. | SANGER | ||
| OPM-2 | Growth Inhibition Assay | Inhibition of human OPM-2 cell growth in a cell viability assay, IC50 = 1.65801 μM. | SANGER | ||
| TE-8 | Growth Inhibition Assay | Inhibition of human TE-8 cell growth in a cell viability assay, IC50 = 1.679 μM. | SANGER | ||
| MFE-296 | Growth Inhibition Assay | Inhibition of human MFE-296 cell growth in a cell viability assay, IC50 = 1.67951 μM. | SANGER | ||
| 8305C | Growth Inhibition Assay | Inhibition of human 8305C cell growth in a cell viability assay, IC50 = 1.68034 μM. | SANGER | ||
| IGROV-1 | Growth Inhibition Assay | Inhibition of human IGROV-1 cell growth in a cell viability assay, IC50 = 1.69317 μM. | SANGER | ||
| HCC2157 | Growth Inhibition Assay | Inhibition of human HCC2157 cell growth in a cell viability assay, IC50 = 1.73898 μM. | SANGER | ||
| NCI-H1436 | Growth Inhibition Assay | Inhibition of human NCI-H1436 cell growth in a cell viability assay, IC50 = 1.74054 μM. | SANGER | ||
| K052 | Growth Inhibition Assay | Inhibition of human K052 cell growth in a cell viability assay, IC50 = 1.74614 μM. | SANGER | ||
| 5637 | Growth Inhibition Assay | Inhibition of human 5637 cell growth in a cell viability assay, IC50 = 1.77422 μM. | SANGER | ||
| NCI-H747 | Growth Inhibition Assay | Inhibition of human NCI-H747 cell growth in a cell viability assay, IC50 = 1.77706 μM. | SANGER | ||
| UMC-11 | Growth Inhibition Assay | Inhibition of human UMC-11 cell growth in a cell viability assay, IC50 = 1.78278 μM. | SANGER | ||
| SJRH30 | Growth Inhibition Assay | Inhibition of human SJRH30 cell growth in a cell viability assay, IC50 = 1.7888 μM. | SANGER | ||
| HMV-II | Growth Inhibition Assay | Inhibition of human HMV-II cell growth in a cell viability assay, IC50 = 1.79386 μM. | SANGER | ||
| HSC-3 | Growth Inhibition Assay | Inhibition of human HSC-3 cell growth in a cell viability assay, IC50 = 1.81675 μM. | SANGER | ||
| CESS | Growth Inhibition Assay | Inhibition of human CESS cell growth in a cell viability assay, IC50 = 1.8191 μM. | SANGER | ||
| MN-60 | Growth Inhibition Assay | Inhibition of human MN-60 cell growth in a cell viability assay, IC50 = 1.83489 μM. | SANGER | ||
| OVCAR-4 | Growth Inhibition Assay | Inhibition of human OVCAR-4 cell growth in a cell viability assay, IC50 = 1.8477 μM. | SANGER | ||
| RCC10RGB | Growth Inhibition Assay | Inhibition of human RCC10RGB cell growth in a cell viability assay, IC50 = 1.85868 μM. | SANGER | ||
| Caov-4 | Growth Inhibition Assay | Inhibition of human Caov-4 cell growth in a cell viability assay, IC50 = 1.91696 μM. | SANGER | ||
| T-24 | Growth Inhibition Assay | Inhibition of human T-24 cell growth in a cell viability assay, IC50 = 1.91893 μM. | SANGER | ||
| HCE-T | Growth Inhibition Assay | Inhibition of human HCE-T cell growth in a cell viability assay, IC50 = 1.93451 μM. | SANGER | ||
| NCI-H1618 | Growth Inhibition Assay | Inhibition of human NCI-H1618 cell growth in a cell viability assay, IC50 = 1.95521 μM. | SANGER | ||
| GOTO | Growth Inhibition Assay | Inhibition of human GOTO cell growth in a cell viability assay, IC50 = 1.95832 μM. | SANGER | ||
| CTV-1 | Growth Inhibition Assay | Inhibition of human CTV-1 cell growth in a cell viability assay, IC50 = 2.01635 μM. | SANGER | ||
| NCI-H661 | Growth Inhibition Assay | Inhibition of human NCI-H661 cell growth in a cell viability assay, IC50 = 2.02361 μM. | SANGER | ||
| OVCAR-8 | Growth Inhibition Assay | Inhibition of human OVCAR-8 cell growth in a cell viability assay, IC50 = 2.0315 μM. | SANGER | ||
| OCI-AML2 | Growth Inhibition Assay | Inhibition of human OCI-AML2 cell growth in a cell viability assay, IC50 = 2.07476 μM. | SANGER | ||
| GP5d | Growth Inhibition Assay | Inhibition of human GP5d cell growth in a cell viability assay, IC50 = 2.07534 μM. | SANGER | ||
| IM-9 | Growth Inhibition Assay | Inhibition of human IM-9 cell growth in a cell viability assay, IC50 = 2.10517 μM. | SANGER | ||
| Calu-1 | Growth Inhibition Assay | Inhibition of human Calu-1 cell growth in a cell viability assay, IC50 = 2.12405 μM. | SANGER | ||
| LC-1F | Growth Inhibition Assay | Inhibition of human LC-1F cell growth in a cell viability assay, IC50 = 2.14764 μM. | SANGER | ||
| NEC8 | Growth Inhibition Assay | Inhibition of human NEC8 cell growth in a cell viability assay, IC50 = 2.15601 μM. | SANGER | ||
| SK-MM-2 | Growth Inhibition Assay | Inhibition of human SK-MM-2 cell growth in a cell viability assay, IC50 = 2.17622 μM. | SANGER | ||
| BHT-101 | Growth Inhibition Assay | Inhibition of human BHT-101 cell growth in a cell viability assay, IC50 = 2.19654 μM. | SANGER | ||
| IST-MEL1 | Growth Inhibition Assay | Inhibition of human IST-MEL1 cell growth in a cell viability assay, IC50 = 2.2183 μM. | SANGER | ||
| NCI-H1648 | Growth Inhibition Assay | Inhibition of human NCI-H1648 cell growth in a cell viability assay, IC50 = 2.23428 μM. | SANGER | ||
| DV-90 | Growth Inhibition Assay | Inhibition of human DV-90 cell growth in a cell viability assay, IC50 = 2.24215 μM. | SANGER | ||
| CAPAN-1 | Growth Inhibition Assay | Inhibition of human CAPAN-1 cell growth in a cell viability assay, IC50 = 2.24787 μM. | SANGER | ||
| C-33-A | Growth Inhibition Assay | Inhibition of human C-33-A cell growth in a cell viability assay, IC50 = 2.26063 μM. | SANGER | ||
| SW1573 | Growth Inhibition Assay | Inhibition of human SW1573 cell growth in a cell viability assay, IC50 = 2.28472 μM. | SANGER | ||
| NCI-H1304 | Growth Inhibition Assay | Inhibition of human NCI-H1304 cell growth in a cell viability assay, IC50 = 2.28867 μM. | SANGER | ||
| RCM-1 | Growth Inhibition Assay | Inhibition of human RCM-1 cell growth in a cell viability assay, IC50 = 2.29298 μM. | SANGER | ||
| KINGS-1 | Growth Inhibition Assay | Inhibition of human KINGS-1 cell growth in a cell viability assay, IC50 = 2.30271 μM. | SANGER | ||
| Hs-578-T | Growth Inhibition Assay | Inhibition of human Hs-578-T cell growth in a cell viability assay, IC50 = 2.30709 μM. | SANGER | ||
| KLE | Growth Inhibition Assay | Inhibition of human KLE cell growth in a cell viability assay, IC50 = 2.30734 μM. | SANGER | ||
| BHY | Growth Inhibition Assay | Inhibition of human BHY cell growth in a cell viability assay, IC50 = 2.34912 μM. | SANGER | ||
| WM-115 | Growth Inhibition Assay | Inhibition of human WM-115 cell growth in a cell viability assay, IC50 = 2.35968 μM. | SANGER | ||
| JiyoyeP-2003 | Growth Inhibition Assay | Inhibition of human JiyoyeP-2003 cell growth in a cell viability assay, IC50 = 2.36405 μM. | SANGER | ||
| NCI-H2228 | Growth Inhibition Assay | Inhibition of human NCI-H2228 cell growth in a cell viability assay, IC50 = 2.38384 μM. | SANGER | ||
| NCI-H226 | Growth Inhibition Assay | Inhibition of human NCI-H226 cell growth in a cell viability assay, IC50 = 2.38663 μM. | SANGER | ||
| HCC70 | Growth Inhibition Assay | Inhibition of human HCC70 cell growth in a cell viability assay, IC50 = 2.44949 μM. | SANGER | ||
| SK-PN-DW | Growth Inhibition Assay | Inhibition of human SK-PN-DW cell growth in a cell viability assay, IC50 = 2.46029 μM. | SANGER | ||
| KYSE-450 | Growth Inhibition Assay | Inhibition of human KYSE-450 cell growth in a cell viability assay, IC50 = 2.59202 μM. | SANGER | ||
| SN12C | Growth Inhibition Assay | Inhibition of human SN12C cell growth in a cell viability assay, IC50 = 2.6275 μM. | SANGER | ||
| U-87-MG | Growth Inhibition Assay | Inhibition of human U-87-MG cell growth in a cell viability assay, IC50 = 2.68124 μM. | SANGER | ||
| Becker | Growth Inhibition Assay | Inhibition of human Becker cell growth in a cell viability assay, IC50 = 2.69475 μM. | SANGER | ||
| NCI-SNU-1 | Growth Inhibition Assay | Inhibition of human NCI-SNU-1 cell growth in a cell viability assay, IC50 = 2.70325 μM. | SANGER | ||
| IST-SL1 | Growth Inhibition Assay | Inhibition of human IST-SL1 cell growth in a cell viability assay, IC50 = 2.70327 μM. | SANGER | ||
| SIMA | Growth Inhibition Assay | Inhibition of human SIMA cell growth in a cell viability assay, IC50 = 2.7086 μM. | SANGER | ||
| IMR-5 | Growth Inhibition Assay | Inhibition of human IMR-5 cell growth in a cell viability assay, IC50 = 2.71465 μM. | SANGER | ||
| COLO-678 | Growth Inhibition Assay | Inhibition of human COLO-678 cell growth in a cell viability assay, IC50 = 2.73477 μM. | SANGER | ||
| LS-411N | Growth Inhibition Assay | Inhibition of human LS-411N cell growth in a cell viability assay, IC50 = 2.74999 μM. | SANGER | ||
| Capan-2 | Growth Inhibition Assay | Inhibition of human Capan-2 cell growth in a cell viability assay, IC50 = 2.7664 μM. | SANGER | ||
| HT55 | Growth Inhibition Assay | Inhibition of human HT55 cell growth in a cell viability assay, IC50 = 2.77321 μM. | SANGER | ||
| RPMI-2650 | Growth Inhibition Assay | Inhibition of human RPMI-2650 cell growth in a cell viability assay, IC50 = 2.78633 μM. | SANGER | ||
| HuH-7 | Growth Inhibition Assay | Inhibition of human HuH-7 cell growth in a cell viability assay, IC50 = 2.78923 μM. | SANGER | ||
| NCI-H2452 | Growth Inhibition Assay | Inhibition of human NCI-H2452 cell growth in a cell viability assay, IC50 = 2.80514 μM. | SANGER | ||
| RMG-I | Growth Inhibition Assay | Inhibition of human RMG-I cell growth in a cell viability assay, IC50 = 2.86407 μM. | SANGER | ||
| NCI-H2347 | Growth Inhibition Assay | Inhibition of human NCI-H2347 cell growth in a cell viability assay, IC50 = 2.86973 μM. | SANGER | ||
| COLO-824 | Growth Inhibition Assay | Inhibition of human COLO-824 cell growth in a cell viability assay, IC50 = 2.88433 μM. | SANGER | ||
| HC-1 | Growth Inhibition Assay | Inhibition of human HC-1 cell growth in a cell viability assay, IC50 = 2.89529 μM. | SANGER | ||
| ChaGo-K-1 | Growth Inhibition Assay | Inhibition of human ChaGo-K-1 cell growth in a cell viability assay, IC50 = 2.89815 μM. | SANGER | ||
| Ramos-2G6-4C10 | Growth Inhibition Assay | Inhibition of human Ramos-2G6-4C10 cell growth in a cell viability assay, IC50 = 2.94387 μM. | SANGER | ||
| SK-MEL-2 | Growth Inhibition Assay | Inhibition of human SK-MEL-2 cell growth in a cell viability assay, IC50 = 2.97003 μM. | SANGER | ||
| NCI-H64 | Growth Inhibition Assay | Inhibition of human NCI-H64 cell growth in a cell viability assay, IC50 = 3.00372 μM. | SANGER | ||
| MHH-NB-11 | Growth Inhibition Assay | Inhibition of human MHH-NB-11 cell growth in a cell viability assay, IC50 = 3.01878 μM. | SANGER | ||
| SU-DHL-1 | Growth Inhibition Assay | Inhibition of human SU-DHL-1 cell growth in a cell viability assay, IC50 = 3.06959 μM. | SANGER | ||
| NOS-1 | Growth Inhibition Assay | Inhibition of human NOS-1 cell growth in a cell viability assay, IC50 = 3.09872 μM. | SANGER | ||
| ARH-77 | Growth Inhibition Assay | Inhibition of human ARH-77 cell growth in a cell viability assay, IC50 = 3.14605 μM. | SANGER | ||
| HO-1-N-1 | Growth Inhibition Assay | Inhibition of human HO-1-N-1 cell growth in a cell viability assay, IC50 = 3.15569 μM. | SANGER | ||
| TGBC1TKB | Growth Inhibition Assay | Inhibition of human TGBC1TKB cell growth in a cell viability assay, IC50 = 3.17557 μM. | SANGER | ||
| HuP-T3 | Growth Inhibition Assay | Inhibition of human HuP-T3 cell growth in a cell viability assay, IC50 = 3.2079 μM. | SANGER | ||
| BEN | Growth Inhibition Assay | Inhibition of human BEN cell growth in a cell viability assay, IC50 = 3.21481 μM. | SANGER | ||
| HGC-27 | Growth Inhibition Assay | Inhibition of human HGC-27 cell growth in a cell viability assay, IC50 = 3.2299 μM. | SANGER | ||
| no-11 | Growth Inhibition Assay | Inhibition of human no-11 cell growth in a cell viability assay, IC50 = 3.23209 μM. | SANGER | ||
| NCI-H460 | Growth Inhibition Assay | Inhibition of human NCI-H460 cell growth in a cell viability assay, IC50 = 3.26306 μM. | SANGER | ||
| COLO-684 | Growth Inhibition Assay | Inhibition of human COLO-684 cell growth in a cell viability assay, IC50 = 3.34745 μM. | SANGER | ||
| RPMI-6666 | Growth Inhibition Assay | Inhibition of human RPMI-6666 cell growth in a cell viability assay, IC50 = 3.41159 μM. | SANGER | ||
| NCI-H1993 | Growth Inhibition Assay | Inhibition of human NCI-H1993 cell growth in a cell viability assay, IC50 = 3.53667 μM. | SANGER | ||
| IPC-298 | Growth Inhibition Assay | Inhibition of human IPC-298 cell growth in a cell viability assay, IC50 = 3.55672 μM. | SANGER | ||
| NCI-H1437 | Growth Inhibition Assay | Inhibition of human NCI-H1437 cell growth in a cell viability assay, IC50 = 3.55932 μM. | SANGER | ||
| COR-L279 | Growth Inhibition Assay | Inhibition of human COR-L279 cell growth in a cell viability assay, IC50 = 3.56357 μM. | SANGER | ||
| BT-20 | Growth Inhibition Assay | Inhibition of human BT-20 cell growth in a cell viability assay, IC50 = 3.6653 μM. | SANGER | ||
| LK-2 | Growth Inhibition Assay | Inhibition of human LK-2 cell growth in a cell viability assay, IC50 = 3.71552 μM. | SANGER | ||
| Saos-2 | Growth Inhibition Assay | Inhibition of human Saos-2 cell growth in a cell viability assay, IC50 = 3.7428 μM. | SANGER | ||
| SKG-IIIa | Growth Inhibition Assay | Inhibition of human SKG-IIIa cell growth in a cell viability assay, IC50 = 3.76572 μM. | SANGER | ||
| MC-CAR | Growth Inhibition Assay | Inhibition of human MC-CAR cell growth in a cell viability assay, IC50 = 3.78133 μM. | SANGER | ||
| UACC-257 | Growth Inhibition Assay | Inhibition of human UACC-257 cell growth in a cell viability assay, IC50 = 3.81844 μM. | SANGER | ||
| DU-4475 | Growth Inhibition Assay | Inhibition of human DU-4475 cell growth in a cell viability assay, IC50 = 3.87134 μM. | SANGER | ||
| RERF-LC-MS | Growth Inhibition Assay | Inhibition of human RERF-LC-MS cell growth in a cell viability assay, IC50 = 3.98353 μM. | SANGER | ||
| LB996-RCC | Growth Inhibition Assay | Inhibition of human LB996-RCC cell growth in a cell viability assay, IC50 = 3.98644 μM. | SANGER | ||
| ES3 | Growth Inhibition Assay | Inhibition of human ES3 cell growth in a cell viability assay, IC50 = 4.05557 μM. | SANGER | ||
| MMAC-SF | Growth Inhibition Assay | Inhibition of human MMAC-SF cell growth in a cell viability assay, IC50 = 4.05847 μM. | SANGER | ||
| MEG-01 | Growth Inhibition Assay | Inhibition of human MEG-01 cell growth in a cell viability assay, IC50 = 4.06297 μM. | SANGER | ||
| TE-1 | Growth Inhibition Assay | Inhibition of human TE-1 cell growth in a cell viability assay, IC50 = 4.09458 μM. | SANGER | ||
| ES6 | Growth Inhibition Assay | Inhibition of human ES6 cell growth in a cell viability assay, IC50 = 4.10666 μM. | SANGER | ||
| NCI-H1963 | Growth Inhibition Assay | Inhibition of human NCI-H1963 cell growth in a cell viability assay, IC50 = 4.11351 μM. | SANGER | ||
| MZ7-mel | Growth Inhibition Assay | Inhibition of human MZ7-mel cell growth in a cell viability assay, IC50 = 4.15662 μM. | SANGER | ||
| COLO-679 | Growth Inhibition Assay | Inhibition of human COLO-679 cell growth in a cell viability assay, IC50 = 4.16629 μM. | SANGER | ||
| LB647-SCLC | Growth Inhibition Assay | Inhibition of human LB647-SCLC cell growth in a cell viability assay, IC50 = 4.22508 μM. | SANGER | ||
| LoVo | Growth Inhibition Assay | Inhibition of human LoVo cell growth in a cell viability assay, IC50 = 4.22985 μM. | SANGER | ||
| UACC-62 | Growth Inhibition Assay | Inhibition of human UACC-62 cell growth in a cell viability assay, IC50 = 4.25764 μM. | SANGER | ||
| BE-13 | Growth Inhibition Assay | Inhibition of human BE-13 cell growth in a cell viability assay, IC50 = 4.36027 μM. | SANGER | ||
| SW962 | Growth Inhibition Assay | Inhibition of human SW962 cell growth in a cell viability assay, IC50 = 4.36427 μM. | SANGER | ||
| HEC-1 | Growth Inhibition Assay | Inhibition of human HEC-1 cell growth in a cell viability assay, IC50 = 4.39433 μM. | SANGER | ||
| KOSC-2 | Growth Inhibition Assay | Inhibition of human KOSC-2 cell growth in a cell viability assay, IC50 = 4.39928 μM. | SANGER | ||
| HSC-4 | Growth Inhibition Assay | Inhibition of human HSC-4 cell growth in a cell viability assay, IC50 = 4.40337 μM. | SANGER | ||
| J82 | Growth Inhibition Assay | Inhibition of human J82 cell growth in a cell viability assay, IC50 = 4.43178 μM. | SANGER | ||
| MLMA | Growth Inhibition Assay | Inhibition of human MLMA cell growth in a cell viability assay, IC50 = 4.4609 μM. | SANGER | ||
| LU-165 | Growth Inhibition Assay | Inhibition of human LU-165 cell growth in a cell viability assay, IC50 = 4.46513 μM. | SANGER | ||
| C8166 | Growth Inhibition Assay | Inhibition of human C8166 cell growth in a cell viability assay, IC50 = 4.48793 μM. | SANGER | ||
| LC4-1 | Growth Inhibition Assay | Inhibition of human LC4-1 cell growth in a cell viability assay, IC50 = 4.51096 μM. | SANGER | ||
| RT4 | Growth Inhibition Assay | Inhibition of human RT4 cell growth in a cell viability assay, IC50 = 4.61734 μM. | SANGER | ||
| 23132-87 | Growth Inhibition Assay | Inhibition of human 23132-87 cell growth in a cell viability assay, IC50 = 4.63837 μM. | SANGER | ||
| COLO-320-HSR | Growth Inhibition Assay | Inhibition of human COLO-320-HSR cell growth in a cell viability assay, IC50 = 4.64656 μM. | SANGER | ||
| KARPAS-45 | Growth Inhibition Assay | Inhibition of human KARPAS-45 cell growth in a cell viability assay, IC50 = 4.65165 μM. | SANGER | ||
| LU-65 | Growth Inhibition Assay | Inhibition of human LU-65 cell growth in a cell viability assay, IC50 = 4.65198 μM. | SANGER | ||
| PC-3 | Growth Inhibition Assay | Inhibition of human PC-3 cell growth in a cell viability assay, IC50 = 4.66509 μM. | SANGER | ||
| IA-LM | Growth Inhibition Assay | Inhibition of human IA-LM cell growth in a cell viability assay, IC50 = 4.70635 μM. | SANGER | ||
| SW684 | Growth Inhibition Assay | Inhibition of human SW684 cell growth in a cell viability assay, IC50 = 4.78838 μM. | SANGER | ||
| MDA-MB-134-VI | Growth Inhibition Assay | Inhibition of human MDA-MB-134-VI cell growth in a cell viability assay, IC50 = 4.79107 μM. | SANGER | ||
| KMOE-2 | Growth Inhibition Assay | Inhibition of human KMOE-2 cell growth in a cell viability assay, IC50 = 4.79789 μM. | SANGER | ||
| PANC-08-13 | Growth Inhibition Assay | Inhibition of human PANC-08-13 cell growth in a cell viability assay, IC50 = 4.80463 μM. | SANGER | ||
| NB12 | Growth Inhibition Assay | Inhibition of human NB12 cell growth in a cell viability assay, IC50 = 4.83764 μM. | SANGER | ||
| CHP-126 | Growth Inhibition Assay | Inhibition of human CHP-126 cell growth in a cell viability assay, IC50 = 4.84468 μM. | SANGER | ||
| HH | Growth Inhibition Assay | Inhibition of human HH cell growth in a cell viability assay, IC50 = 4.89303 μM. | SANGER | ||
| A253 | Growth Inhibition Assay | Inhibition of human A253 cell growth in a cell viability assay, IC50 = 4.90307 μM. | SANGER | ||
| MS-1 | Growth Inhibition Assay | Inhibition of human MS-1 cell growth in a cell viability assay, IC50 = 4.92448 μM. | SANGER | ||
| OE33 | Growth Inhibition Assay | Inhibition of human OE33 cell growth in a cell viability assay, IC50 = 4.98609 μM. | SANGER | ||
| LU-134-A | Growth Inhibition Assay | Inhibition of human LU-134-A cell growth in a cell viability assay, IC50 = 5.00007 μM. | SANGER | ||
| NCI-H441 | Growth Inhibition Assay | Inhibition of human NCI-H441 cell growth in a cell viability assay, IC50 = 5.07203 μM. | SANGER | ||
| Daudi | Growth Inhibition Assay | Inhibition of human Daudi cell growth in a cell viability assay, IC50 = 5.09119 μM. | SANGER | ||
| EHEB | Growth Inhibition Assay | Inhibition of human EHEB cell growth in a cell viability assay, IC50 = 5.11224 μM. | SANGER | ||
| SNU-C1 | Growth Inhibition Assay | Inhibition of human SNU-C1 cell growth in a cell viability assay, IC50 = 5.16875 μM. | SANGER | ||
| TGBC24TKB | Growth Inhibition Assay | Inhibition of human TGBC24TKB cell growth in a cell viability assay, IC50 = 5.20055 μM. | SANGER | ||
| T47D | Growth Inhibition Assay | Inhibition of human T47D cell growth in a cell viability assay, IC50 = 5.24803 μM. | SANGER | ||
| NCI-N87 | Growth Inhibition Assay | Inhibition of human NCI-N87 cell growth in a cell viability assay, IC50 = 5.32699 μM. | SANGER | ||
| MFE-280 | Growth Inhibition Assay | Inhibition of human MFE-280 cell growth in a cell viability assay, IC50 = 5.39569 μM. | SANGER | ||
| KNS-81-FD | Growth Inhibition Assay | Inhibition of human KNS-81-FD cell growth in a cell viability assay, IC50 = 5.43617 μM. | SANGER | ||
| BV-173 | Growth Inhibition Assay | Inhibition of human BV-173 cell growth in a cell viability assay, IC50 = 5.44899 μM. | SANGER | ||
| L-363 | Growth Inhibition Assay | Inhibition of human L-363 cell growth in a cell viability assay, IC50 = 5.48279 μM. | SANGER | ||
| SW1417 | Growth Inhibition Assay | Inhibition of human SW1417 cell growth in a cell viability assay, IC50 = 5.50405 μM. | SANGER | ||
| OE19 | Growth Inhibition Assay | Inhibition of human OE19 cell growth in a cell viability assay, IC50 = 5.51721 μM. | SANGER | ||
| AU565 | Growth Inhibition Assay | Inhibition of human AU565 cell growth in a cell viability assay, IC50 = 5.54849 μM. | SANGER | ||
| EB-3 | Growth Inhibition Assay | Inhibition of human EB-3 cell growth in a cell viability assay, IC50 = 5.59768 μM. | SANGER | ||
| LS-123 | Growth Inhibition Assay | Inhibition of human LS-123 cell growth in a cell viability assay, IC50 = 5.63714 μM. | SANGER | ||
| Detroit562 | Growth Inhibition Assay | Inhibition of human Detroit562 cell growth in a cell viability assay, IC50 = 5.66765 μM. | SANGER | ||
| MZ2-MEL | Growth Inhibition Assay | Inhibition of human MZ2-MEL cell growth in a cell viability assay, IC50 = 5.66902 μM. | SANGER | ||
| SK-OV-3 | Growth Inhibition Assay | Inhibition of human SK-OV-3 cell growth in a cell viability assay, IC50 = 5.7181 μM. | SANGER | ||
| BB49-HNC | Growth Inhibition Assay | Inhibition of human BB49-HNC cell growth in a cell viability assay, IC50 = 5.7794 μM. | SANGER | ||
| L-428 | Growth Inhibition Assay | Inhibition of human L-428 cell growth in a cell viability assay, IC50 = 5.83896 μM. | SANGER | ||
| D-502MG | Growth Inhibition Assay | Inhibition of human D-502MG cell growth in a cell viability assay, IC50 = 5.84231 μM. | SANGER | ||
| IST-SL2 | Growth Inhibition Assay | Inhibition of human IST-SL2 cell growth in a cell viability assay, IC50 = 6.00753 μM. | SANGER | ||
| MHH-PREB-1 | Growth Inhibition Assay | Inhibition of human MHH-PREB-1 cell growth in a cell viability assay, IC50 = 6.09945 μM. | SANGER | ||
| LB2518-MEL | Growth Inhibition Assay | Inhibition of human LB2518-MEL cell growth in a cell viability assay, IC50 = 6.25712 μM. | SANGER | ||
| MOLT-16 | Growth Inhibition Assay | Inhibition of human MOLT-16 cell growth in a cell viability assay, IC50 = 6.37751 μM. | SANGER | ||
| EW-3 | Growth Inhibition Assay | Inhibition of human EW-3 cell growth in a cell viability assay, IC50 = 6.49826 μM. | SANGER | ||
| SW13 | Growth Inhibition Assay | Inhibition of human SW13 cell growth in a cell viability assay, IC50 = 6.54451 μM. | SANGER | ||
| MDA-MB-175-VII | Growth Inhibition Assay | Inhibition of human MDA-MB-175-VII cell growth in a cell viability assay, IC50 = 6.59915 μM. | SANGER | ||
| NCI-H1651 | Growth Inhibition Assay | Inhibition of human NCI-H1651 cell growth in a cell viability assay, IC50 = 6.70771 μM. | SANGER | ||
| TE-9 | Growth Inhibition Assay | Inhibition of human TE-9 cell growth in a cell viability assay, IC50 = 6.72501 μM. | SANGER | ||
| MOLT-4 | Growth Inhibition Assay | Inhibition of human MOLT-4 cell growth in a cell viability assay, IC50 = 6.73673 μM. | SANGER | ||
| SHP-77 | Growth Inhibition Assay | Inhibition of human SHP-77 cell growth in a cell viability assay, IC50 = 6.87231 μM. | SANGER | ||
| HN | Growth Inhibition Assay | Inhibition of human HN cell growth in a cell viability assay, IC50 = 6.99041 μM. | SANGER | ||
| NCI-H2196 | Growth Inhibition Assay | Inhibition of human NCI-H2196 cell growth in a cell viability assay, IC50 = 7.07134 μM. | SANGER | ||
| HT-3 | Growth Inhibition Assay | Inhibition of human HT-3 cell growth in a cell viability assay, IC50 = 7.10261 μM. | SANGER | ||
| SNU-475 | Growth Inhibition Assay | Inhibition of human SNU-475 cell growth in a cell viability assay, IC50 = 7.24992 μM. | SANGER | ||
| LAMA-84 | Growth Inhibition Assay | Inhibition of human LAMA-84 cell growth in a cell viability assay, IC50 = 7.26693 μM. | SANGER | ||
| BL-70 | Growth Inhibition Assay | Inhibition of human BL-70 cell growth in a cell viability assay, IC50 = 7.58685 μM. | SANGER | ||
| HCC1187 | Growth Inhibition Assay | Inhibition of human HCC1187 cell growth in a cell viability assay, IC50 = 7.90746 μM. | SANGER | ||
| CHL-1 | Growth Inhibition Assay | Inhibition of human CHL-1 cell growth in a cell viability assay, IC50 = 7.9551 μM. | SANGER | ||
| LOXIMVI | Growth Inhibition Assay | Inhibition of human LOXIMVI cell growth in a cell viability assay, IC50 = 7.98834 μM. | SANGER | ||
| NCI-H748 | Growth Inhibition Assay | Inhibition of human NCI-H748 cell growth in a cell viability assay, IC50 = 8.06778 μM. | SANGER | ||
| LB771-HNC | Growth Inhibition Assay | Inhibition of human LB771-HNC cell growth in a cell viability assay, IC50 = 8.1383 μM. | SANGER | ||
| JVM-2 | Growth Inhibition Assay | Inhibition of human JVM-2 cell growth in a cell viability assay, IC50 = 8.22065 μM. | SANGER | ||
| SJSA-1 | Growth Inhibition Assay | Inhibition of human SJSA-1 cell growth in a cell viability assay, IC50 = 8.40363 μM. | SANGER | ||
| SW1990 | Growth Inhibition Assay | Inhibition of human SW1990 cell growth in a cell viability assay, IC50 = 8.47225 μM. | SANGER | ||
| NB5 | Growth Inhibition Assay | Inhibition of human NB5 cell growth in a cell viability assay, IC50 = 8.64343 μM. | SANGER | ||
| ATN-1 | Growth Inhibition Assay | Inhibition of human ATN-1 cell growth in a cell viability assay, IC50 = 8.65295 μM. | SANGER | ||
| HAL-01 | Growth Inhibition Assay | Inhibition of human HAL-01 cell growth in a cell viability assay, IC50 = 8.74413 μM. | SANGER | ||
| LU-139 | Growth Inhibition Assay | Inhibition of human LU-139 cell growth in a cell viability assay, IC50 = 8.92615 μM. | SANGER | ||
| no-10 | Growth Inhibition Assay | Inhibition of human no-10 cell growth in a cell viability assay, IC50 = 9.30633 μM. | SANGER | ||
| NCI-H1694 | Growth Inhibition Assay | Inhibition of human NCI-H1694 cell growth in a cell viability assay, IC50 = 9.37253 μM. | SANGER | ||
| COR-L88 | Growth Inhibition Assay | Inhibition of human COR-L88 cell growth in a cell viability assay, IC50 = 9.60055 μM. | SANGER | ||
| 22RV1 | Growth Inhibition Assay | Inhibition of human 22RV1 cell growth in a cell viability assay, IC50 = 9.72382 μM. | SANGER | ||
| KM-H2 | Growth Inhibition Assay | Inhibition of human KM-H2 cell growth in a cell viability assay, IC50 = 9.7619 μM. | SANGER | ||
| NCI-H1092 | Growth Inhibition Assay | Inhibition of human NCI-H1092 cell growth in a cell viability assay, IC50 = 9.79253 μM. | SANGER | ||
| AsPC-1 | Growth Inhibition Assay | Inhibition of human AsPC-1 cell growth in a cell viability assay, IC50 = 9.85935 μM. | SANGER | ||
| MHH-CALL-2 | Growth Inhibition Assay | Inhibition of human MHH-CALL-2 cell growth in a cell viability assay, IC50 = 10.0169 μM. | SANGER | ||
| NCI-SNU-5 | Growth Inhibition Assay | Inhibition of human NCI-SNU-5 cell growth in a cell viability assay, IC50 = 10.3242 μM. | SANGER | ||
| BPH-1 | Growth Inhibition Assay | Inhibition of human BPH-1 cell growth in a cell viability assay, IC50 = 10.3777 μM. | SANGER | ||
| P12-ICHIKAWA | Growth Inhibition Assay | Inhibition of human P12-ICHIKAWA cell growth in a cell viability assay, IC50 = 11.1095 μM. | SANGER | ||
| NCI-H727 | Growth Inhibition Assay | Inhibition of human NCI-H727 cell growth in a cell viability assay, IC50 = 11.1392 μM. | SANGER | ||
| COR-L23 | Growth Inhibition Assay | Inhibition of human COR-L23 cell growth in a cell viability assay, IC50 = 11.1878 μM. | SANGER | ||
| U-118-MG | Growth Inhibition Assay | Inhibition of human U-118-MG cell growth in a cell viability assay, IC50 = 11.2779 μM. | SANGER | ||
| GAK | Growth Inhibition Assay | Inhibition of human GAK cell growth in a cell viability assay, IC50 = 11.3348 μM. | SANGER | ||
| HCC2998 | Growth Inhibition Assay | Inhibition of human HCC2998 cell growth in a cell viability assay, IC50 = 11.4251 μM. | SANGER | ||
| COLO-829 | Growth Inhibition Assay | Inhibition of human COLO-829 cell growth in a cell viability assay, IC50 = 11.6192 μM. | SANGER | ||
| CAL-33 | Growth Inhibition Assay | Inhibition of human CAL-33 cell growth in a cell viability assay, IC50 = 11.9946 μM. | SANGER | ||
| EB2 | Growth Inhibition Assay | Inhibition of human EB2 cell growth in a cell viability assay, IC50 = 11.9968 μM. | SANGER | ||
| THP-1 | Growth Inhibition Assay | Inhibition of human THP-1 cell growth in a cell viability assay, IC50 = 12.0748 μM. | SANGER | ||
| ES1 | Growth Inhibition Assay | Inhibition of human ES1 cell growth in a cell viability assay, IC50 = 12.0862 μM. | SANGER | ||
| 647-V | Growth Inhibition Assay | Inhibition of human 647-V cell growth in a cell viability assay, IC50 = 12.0972 μM. | SANGER | ||
| NCI-H520 | Growth Inhibition Assay | Inhibition of human NCI-H520 cell growth in a cell viability assay, IC50 = 12.2896 μM. | SANGER | ||
| JEG-3 | Growth Inhibition Assay | Inhibition of human JEG-3 cell growth in a cell viability assay, IC50 = 12.5281 μM. | SANGER | ||
| A388 | Growth Inhibition Assay | Inhibition of human A388 cell growth in a cell viability assay, IC50 = 12.6997 μM. | SANGER | ||
| Mewo | Growth Inhibition Assay | Inhibition of human Mewo cell growth in a cell viability assay, IC50 = 12.8578 μM. | SANGER | ||
| KNS-42 | Growth Inhibition Assay | Inhibition of human KNS-42 cell growth in a cell viability assay, IC50 = 12.9918 μM. | SANGER | ||
| MDA-MB-468 | Growth Inhibition Assay | Inhibition of human MDA-MB-468 cell growth in a cell viability assay, IC50 = 13.0366 μM. | SANGER | ||
| SiHa | Growth Inhibition Assay | Inhibition of human SiHa cell growth in a cell viability assay, IC50 = 13.1045 μM. | SANGER | ||
| C2BBe1 | Growth Inhibition Assay | Inhibition of human C2BBe1 cell growth in a cell viability assay, IC50 = 13.715 μM. | SANGER | ||
| HDLM-2 | Growth Inhibition Assay | Inhibition of human HDLM-2 cell growth in a cell viability assay, IC50 = 13.7375 μM. | SANGER | ||
| PFSK-1 | Growth Inhibition Assay | Inhibition of human PFSK-1 cell growth in a cell viability assay, IC50 = 14.1067 μM. | SANGER | ||
| NCI-H446 | Growth Inhibition Assay | Inhibition of human NCI-H446 cell growth in a cell viability assay, IC50 = 14.3535 μM. | SANGER | ||
| EKVX | Growth Inhibition Assay | Inhibition of human EKVX cell growth in a cell viability assay, IC50 = 14.5135 μM. | SANGER | ||
| DJM-1 | Growth Inhibition Assay | Inhibition of human DJM-1 cell growth in a cell viability assay, IC50 = 14.5549 μM. | SANGER | ||
| K-562 | Growth Inhibition Assay | Inhibition of human K-562 cell growth in a cell viability assay, IC50 = 14.5747 μM. | SANGER | ||
| CP50-MEL-B | Growth Inhibition Assay | Inhibition of human CP50-MEL-B cell growth in a cell viability assay, IC50 = 14.6287 μM. | SANGER | ||
| SK-NEP-1 | Growth Inhibition Assay | Inhibition of human SK-NEP-1 cell growth in a cell viability assay, IC50 = 15.2382 μM. | SANGER | ||
| Ca9-22 | Growth Inhibition Assay | Inhibition of human Ca9-22 cell growth in a cell viability assay, IC50 = 15.3006 μM. | SANGER | ||
| M14 | Growth Inhibition Assay | Inhibition of human M14 cell growth in a cell viability assay, IC50 = 15.8452 μM. | SANGER | ||
| Calu-6 | Growth Inhibition Assay | Inhibition of human Calu-6 cell growth in a cell viability assay, IC50 = 15.9582 μM. | SANGER | ||
| NCI-H1838 | Growth Inhibition Assay | Inhibition of human NCI-H1838 cell growth in a cell viability assay, IC50 = 15.9636 μM. | SANGER | ||
| T84 | Growth Inhibition Assay | Inhibition of human T84 cell growth in a cell viability assay, IC50 = 16.4497 μM. | SANGER | ||
| ME-180 | Growth Inhibition Assay | Inhibition of human ME-180 cell growth in a cell viability assay, IC50 = 17.4632 μM. | SANGER | ||
| LP-1 | Growth Inhibition Assay | Inhibition of human LP-1 cell growth in a cell viability assay, IC50 = 17.5062 μM. | SANGER | ||
| DMS-153 | Growth Inhibition Assay | Inhibition of human DMS-153 cell growth in a cell viability assay, IC50 = 18.0166 μM. | SANGER | ||
| SW1463 | Growth Inhibition Assay | Inhibition of human SW1463 cell growth in a cell viability assay, IC50 = 18.1741 μM. | SANGER | ||
| J-RT3-T3-5 | Growth Inhibition Assay | Inhibition of human J-RT3-T3-5 cell growth in a cell viability assay, IC50 = 18.2392 μM. | SANGER | ||
| Ca-Ski | Growth Inhibition Assay | Inhibition of human Ca-Ski cell growth in a cell viability assay, IC50 = 18.5343 μM. | SANGER | ||
| CAL-148 | Growth Inhibition Assay | Inhibition of human CAL-148 cell growth in a cell viability assay, IC50 = 18.543 μM. | SANGER | ||
| NB10 | Growth Inhibition Assay | Inhibition of human NB10 cell growth in a cell viability assay, IC50 = 18.6146 μM. | SANGER | ||
| HPAF-II | Growth Inhibition Assay | Inhibition of human HPAF-II cell growth in a cell viability assay, IC50 = 19.4871 μM. | SANGER | ||
| CAL-72 | Growth Inhibition Assay | Inhibition of human CAL-72 cell growth in a cell viability assay, IC50 = 20.1775 μM. | SANGER | ||
| TT | Growth Inhibition Assay | Inhibition of human TT cell growth in a cell viability assay, IC50 = 20.2415 μM. | SANGER | ||
| RPMI-8226 | Growth Inhibition Assay | Inhibition of human RPMI-8226 cell growth in a cell viability assay, IC50 = 20.3787 μM. | SANGER | ||
| D-283MED | Growth Inhibition Assay | Inhibition of human D-283MED cell growth in a cell viability assay, IC50 = 20.7314 μM. | SANGER | ||
| MIA-PaCa-2 | Growth Inhibition Assay | Inhibition of human MIA-PaCa-2 cell growth in a cell viability assay, IC50 = 20.74 μM. | SANGER | ||
| CAMA-1 | Growth Inhibition Assay | Inhibition of human CAMA-1 cell growth in a cell viability assay, IC50 = 21.2958 μM. | SANGER | ||
| EW-24 | Growth Inhibition Assay | Inhibition of human EW-24 cell growth in a cell viability assay, IC50 = 21.296 μM. | SANGER | ||
| NCI-H2227 | Growth Inhibition Assay | Inhibition of human NCI-H2227 cell growth in a cell viability assay, IC50 = 21.3845 μM. | SANGER | ||
| SW948 | Growth Inhibition Assay | Inhibition of human SW948 cell growth in a cell viability assay, IC50 = 21.4582 μM. | SANGER | ||
| C32 | Growth Inhibition Assay | Inhibition of human C32 cell growth in a cell viability assay, IC50 = 21.8635 μM. | SANGER | ||
| HL-60 | Growth Inhibition Assay | Inhibition of human HL-60 cell growth in a cell viability assay, IC50 = 22.5901 μM. | SANGER | ||
| SK-MEL-1 | Growth Inhibition Assay | Inhibition of human SK-MEL-1 cell growth in a cell viability assay, IC50 = 22.6933 μM. | SANGER | ||
| D-542MG | Growth Inhibition Assay | Inhibition of human D-542MG cell growth in a cell viability assay, IC50 = 23.1396 μM. | SANGER | ||
| NCI-H2081 | Growth Inhibition Assay | Inhibition of human NCI-H2081 cell growth in a cell viability assay, IC50 = 23.4308 μM. | SANGER | ||
| NOMO-1 | Growth Inhibition Assay | Inhibition of human NOMO-1 cell growth in a cell viability assay, IC50 = 23.5328 μM. | SANGER | ||
| S-117 | Growth Inhibition Assay | Inhibition of human S-117 cell growth in a cell viability assay, IC50 = 24.1114 μM. | SANGER | ||
| KP-N-YS | Growth Inhibition Assay | Inhibition of human KP-N-YS cell growth in a cell viability assay, IC50 = 24.6488 μM. | SANGER | ||
| HCC1937 | Growth Inhibition Assay | Inhibition of human HCC1937 cell growth in a cell viability assay, IC50 = 24.6509 μM. | SANGER | ||
| RVH-421 | Growth Inhibition Assay | Inhibition of human RVH-421 cell growth in a cell viability assay, IC50 = 24.8948 μM. | SANGER | ||
| FTC-133 | Growth Inhibition Assay | Inhibition of human FTC-133 cell growth in a cell viability assay, IC50 = 25.6658 μM. | SANGER | ||
| NCI-H1395 | Growth Inhibition Assay | Inhibition of human NCI-H1395 cell growth in a cell viability assay, IC50 = 25.9419 μM. | SANGER | ||
| KU-19-19 | Growth Inhibition Assay | Inhibition of human KU-19-19 cell growth in a cell viability assay, IC50 = 26.103 μM. | SANGER | ||
| NCI-H1623 | Growth Inhibition Assay | Inhibition of human NCI-H1623 cell growth in a cell viability assay, IC50 = 26.1282 μM. | SANGER | ||
| LB373-MEL-D | Growth Inhibition Assay | Inhibition of human LB373-MEL-D cell growth in a cell viability assay, IC50 = 26.4395 μM. | SANGER | ||
| NCI-H1882 | Growth Inhibition Assay | Inhibition of human NCI-H1882 cell growth in a cell viability assay, IC50 = 26.4574 μM. | SANGER | ||
| HT | Growth Inhibition Assay | Inhibition of human HT cell growth in a cell viability assay, IC50 = 27.1395 μM. | SANGER | ||
| SF539 | Growth Inhibition Assay | Inhibition of human SF539 cell growth in a cell viability assay, IC50 = 27.9248 μM. | SANGER | ||
| NCI-H2171 | Growth Inhibition Assay | Inhibition of human NCI-H2171 cell growth in a cell viability assay, IC50 = 28.6587 μM. | SANGER | ||
| MDA-MB-415 | Growth Inhibition Assay | Inhibition of human MDA-MB-415 cell growth in a cell viability assay, IC50 = 29.1701 μM. | SANGER | ||
| SW756 | Growth Inhibition Assay | Inhibition of human SW756 cell growth in a cell viability assay, IC50 = 29.2866 μM. | SANGER | ||
| MDA-MB-361 | Growth Inhibition Assay | Inhibition of human MDA-MB-361 cell growth in a cell viability assay, IC50 = 29.5408 μM. | SANGER | ||
| NCI-H1581 | Growth Inhibition Assay | Inhibition of human NCI-H1581 cell growth in a cell viability assay, IC50 = 29.8489 μM. | SANGER | ||
| OMC-1 | Growth Inhibition Assay | Inhibition of human OMC-1 cell growth in a cell viability assay, IC50 = 30.0647 μM. | SANGER | ||
| HT-1197 | Growth Inhibition Assay | Inhibition of human HT-1197 cell growth in a cell viability assay, IC50 = 30.4937 μM. | SANGER | ||
| TE-5 | Growth Inhibition Assay | Inhibition of human TE-5 cell growth in a cell viability assay, IC50 = 31.3348 μM. | SANGER | ||
| HCC1419 | Growth Inhibition Assay | Inhibition of human HCC1419 cell growth in a cell viability assay, IC50 = 31.5056 μM. | SANGER | ||
| KE-37 | Growth Inhibition Assay | Inhibition of human KE-37 cell growth in a cell viability assay, IC50 = 31.9635 μM. | SANGER | ||
| DMS-53 | Growth Inhibition Assay | Inhibition of human DMS-53 cell growth in a cell viability assay, IC50 = 32.1035 μM. | SANGER | ||
| EW-11 | Growth Inhibition Assay | Inhibition of human EW-11 cell growth in a cell viability assay, IC50 = 32.9248 μM. | SANGER | ||
| MDA-MB-453 | Growth Inhibition Assay | Inhibition of human MDA-MB-453 cell growth in a cell viability assay, IC50 = 34.2262 μM. | SANGER | ||
| SK-MEL-28 | Growth Inhibition Assay | Inhibition of human SK-MEL-28 cell growth in a cell viability assay, IC50 = 34.81 μM. | SANGER | ||
| HuP-T4 | Growth Inhibition Assay | Inhibition of human HuP-T4 cell growth in a cell viability assay, IC50 = 34.9442 μM. | SANGER | ||
| LNCaP-Clone-FGC | Growth Inhibition Assay | Inhibition of human LNCaP-Clone-FGC cell growth in a cell viability assay, IC50 = 35.3355 μM. | SANGER | ||
| SK-N-AS | Growth Inhibition Assay | Inhibition of human SK-N-AS cell growth in a cell viability assay, IC50 = 35.3997 μM. | SANGER | ||
| NCI-H1417 | Growth Inhibition Assay | Inhibition of human NCI-H1417 cell growth in a cell viability assay, IC50 = 35.644 μM. | SANGER | ||
| SK-N-DZ | Growth Inhibition Assay | Inhibition of human SK-N-DZ cell growth in a cell viability assay, IC50 = 36.2005 μM. | SANGER | ||
| MKN7 | Growth Inhibition Assay | Inhibition of human MKN7 cell growth in a cell viability assay, IC50 = 36.2826 μM. | SANGER | ||
| YAPC | Growth Inhibition Assay | Inhibition of human YAPC cell growth in a cell viability assay, IC50 = 37.0099 μM. | SANGER | ||
| HCC1954 | Growth Inhibition Assay | Inhibition of human HCC1954 cell growth in a cell viability assay, IC50 = 37.4063 μM. | SANGER | ||
| NCI-H209 | Growth Inhibition Assay | Inhibition of human NCI-H209 cell growth in a cell viability assay, IC50 = 37.8896 μM. | SANGER | ||
| NCI-H2141 | Growth Inhibition Assay | Inhibition of human NCI-H2141 cell growth in a cell viability assay, IC50 = 38.0329 μM. | SANGER | ||
| LS-513 | Growth Inhibition Assay | Inhibition of human LS-513 cell growth in a cell viability assay, IC50 = 38.3118 μM. | SANGER | ||
| DOHH-2 | Growth Inhibition Assay | Inhibition of human DOHH-2 cell growth in a cell viability assay, IC50 = 38.9351 μM. | SANGER | ||
| NCI-H596 | Growth Inhibition Assay | Inhibition of human NCI-H596 cell growth in a cell viability assay, IC50 = 39.1801 μM. | SANGER | ||
| TYK-nu | Growth Inhibition Assay | Inhibition of human TYK-nu cell growth in a cell viability assay, IC50 = 40.3953 μM. | SANGER | ||
| CP66-MEL | Growth Inhibition Assay | Inhibition of human CP66-MEL cell growth in a cell viability assay, IC50 = 40.603 μM. | SANGER | ||
| SK-MEL-24 | Growth Inhibition Assay | Inhibition of human SK-MEL-24 cell growth in a cell viability assay, IC50 = 41.4873 μM. | SANGER | ||
| Caov-3 | Growth Inhibition Assay | Inhibition of human Caov-3 cell growth in a cell viability assay, IC50 = 41.5317 μM. | SANGER | ||
| HCC1143 | Growth Inhibition Assay | Inhibition of human HCC1143 cell growth in a cell viability assay, IC50 = 41.6764 μM. | SANGER | ||
| EVSA-T | Growth Inhibition Assay | Inhibition of human EVSA-T cell growth in a cell viability assay, IC50 = 42.8954 μM. | SANGER | ||
| PLC-PRF-5 | Growth Inhibition Assay | Inhibition of human PLC-PRF-5 cell growth in a cell viability assay, IC50 = 44.411 μM. | SANGER | ||
| NCI-H187 | Growth Inhibition Assay | Inhibition of human NCI-H187 cell growth in a cell viability assay, IC50 = 44.9084 μM. | SANGER | ||
| EC-GI-10 | Growth Inhibition Assay | Inhibition of human EC-GI-10 cell growth in a cell viability assay, IC50 = 46.7464 μM. | SANGER | ||
| UACC-893 | Growth Inhibition Assay | Inhibition of human UACC-893 cell growth in a cell viability assay, IC50 = 47.3736 μM. | SANGER | ||
| 他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい | |||||
生物活性
| 製品説明 | Midostaurin is a multi-targeted kinase inhibitor, including PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC50 ranging from 80-500 nM. | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Targets |
|
| In Vitro | ||||
| In vitro | Midostaurin(pkc412) is a broad spectrum protein kinase inhibitor. Midostaurin(pkc412) interacts strongly with ATP binding sites of the conventional PKC-α, -β and -γ, PDGFRβ, VEGF-R2, VEGF-R1 and the cyclin-dependant kinase 1-cyclin B complex. Midostaurin(pkc412) inhibits the growth of various human and animal cell lines in vitro at similar submicromolar concentrations. Midostaurin(pkc412) also effectively inhibits the in vitro proliferation of glioblastoma and induced the accumulation of cells in G2/M and formation of giant nuclei with extensive fragmentation and apoptotic bodies. Midostaurin(pkc412) is able to reverse the p-glycoprotein-mediated multidrug resistance of tumor cells in vitro. [1] | |||
|---|---|---|---|---|
| 細胞実験 | 細胞株 | A549, NCI-H520 | ||
| 濃度 | ~1.0 μM | |||
| 反応時間 | 24-72 h | |||
| 実験の流れ | Each well is added with 5 mM WST-1 and 0.2 mM 1-methoxy PMS and the absorbance at 450 nm is measured by a Microplate Reader. | |||
| 実験結果図 | Methods | Biomarkers | 結果図 | PMID |
| Western blot | p-TYR / p-STAT5 / STAT5 / p-S6 / S6 / p-MAPK / MAPK / p-AKT / AKT PKCα / PKCβ1 / PKCβ2 / PKCγ / PKCη / p-PKC / p-Bad / Bad / p-Bcl2 / Bcl-2 / p-p65 / p65 |
|
28881711 | |
| In Vivo | ||
| In Vivo | Midostaurin(pkc412) may suppress tumor growth by inhibiting tumor angiogenesis (via its effects on the VEGF receptor tyrosine kinases) in addition to directly inhibiting tumor cell proliferation (via its effects on PKCs). This anti-angiogenic action may contribute to the antimetastatic and broad antitumor activity displayed by midostaurin(pkc412), as well as the synergy with cytotoxic agents, including doxorubicin, cyclophosphamide, cisplatin and gemcitabine. When given orally, the maximally tolerated dose for midostaurin(pkc412) is >300 mg/kg. [1] | |
|---|---|---|
| 動物実験 | 動物モデル | Colo 205 colorectal tumors xenograft |
| 投与量 | 50 mg/kg, 200 mg/kg, once daily | |
| 投与経路 | p.o. | |
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT05488613 | Completed | Acute Myeloid Leukemia (AML) |
Novartis Pharmaceuticals|Novartis |
September 24 2020 | -- |
| NCT03951961 | Terminated | Acute Myeloid Leukemia Adult |
University of Jena|Ludwig-Maximilians - University of Munich |
March 20 2020 | Phase 2 |
| NCT04097470 | Active not recruiting | AML/MDS |
Stichting Hemato-Oncologie voor Volwassenen Nederland|Swiss Group for Clinical Cancer Research |
December 5 2019 | Phase 2 |
化学情報
| 分子量 | 570.64 | 化学式 | C35H30N4O4 |
| CAS No. | 120685-11-2 | SDF | Download Midostaurin SDFをダウンロードする |
| Smiles | CC12C(C(CC(O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)CNC6=O)N(C)C(=O)C9=CC=CC=C9)OC | ||
| 保管 | |||
|
In vitro |
DMSO : 100 mg/mL ( (175.24 mM)； 吸湿したDMSOは溶解度を減少させます。新しいDMSOをご使用ください。) Ethanol : 2 mg/mL Water : Insoluble |
モル濃度計算器 |
|
in vivo Add solvents to the product individually and in order. |
投与溶液組成計算機 | ||||
実験計算
投与溶液組成計算機(クリア溶液)
ステップ１：実験データを入力してください。（実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します）
mg/kg
g
μL
匹
ステップ２：投与溶媒の組成を入力してください。（ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください）
% DMSO
%
% Tween 80
% ddH2O
%DMSO
%
計算結果：
投与溶媒濃度： mg/ml;
DMSOストック溶液調製方法： mg 試薬を μL DMSOに溶解する（濃度 mg/mL, 注：濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。 )
投与溶媒調製方法：Take μL DMSOストック溶液に μL PEG300，を加え、完全溶解後μL Tween 80，を加えて完全溶解させた後 μL ddH2O，を加え完全に溶解させます。
投与溶媒調製方法：μL DMSOストック溶液に μL Corn oil，を加え、完全溶解。
注意：１.ストック溶液に沈殿、混濁などがないことをご確認ください；
２.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。
技術サポート
ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。
他に質問がある場合は、お気軽にお問い合わせください。
* 必須
Tags: Midostaurinを買う | Midostaurin ic50 | Midostaurin供給者 | Midostaurinを購入する | Midostaurin費用 | Midostaurin生産者 | オーダーMidostaurin | Midostaurin化学構造 | Midostaurin分子量 | Midostaurin代理店
納期 国内在庫品：受注日の翌日（15時までの受注分） ＊北海道、九州、沖縄への配送は受注日より２日以上 を要する場合あり 海外在庫品：受注後１〜２週間